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Dendritic cells (DC) are uniquely well-equipped, professional antigen-presenting cells (APC), 
with the ability to initiate and regulate immune responses. In transplantation, DC of both donor 
and host origin contribute to graft rejection by inducing T cell activation and proliferation, via 
the direct and indirect pathways of allorecognition, respectively. Evidence has also accumulated, 
however, that DC, particularly in an immature state, can promote tolerance induction and 
prolong organ allograft survival. Rapamycin is a potent immunosuppressant pro-drug that is 
well-recognized for its inhibitory effects on T cell proliferation. Despite extensive research on 
rapamycin’s impact on lymphocytes, little is known to date regarding its effects on DC. The 
central hypothesis in these studies was that, rapamycin interferes with the DC maturation and 
enhances their tolerogenic potential. We first analyzed the influence of rapamycin, in 
pharmacologically-relevant concentrations, on the maturation, functional activation and T cell 
stimulatory potential of murine myeloid DC. Herein we show that rapamycin targets DC antigen 
(Ag)-uptake and IL-4-mediated maturation both in vitro (in bone marrow-derived DC), and in 
vivo (in freshly-isolated DC, following in vivo administration of rapamycin). Exposure to 
rapamycin impairs inflammatory cytokine production and effective T cell stimulation by DC. 
Furthermore, rapamycin-treated DC induce Ag-specific T cell anergy. Next, we determined that 
presentation of alloAgs to T cells by rapamycin-pretreated DC of host origin, under in vivo (pre-
transplant) steady-state conditions, could induce hyporesponsiveness to subsequent challenge 
and prolong organ (heart) graft survival. A single infusion of these cells, seven days prior to 
 iv
transplant, led to a significant improvement in transplant outcome in an Ag-specific manner. 
Furthermore, repeated infusion resulted in marked prolongation of graft survival. These studies 
demonstrate, for the first time, that the immunosuppressive action of rapamycin can be ascribed, 
in part, to its inhibitory effects on DC and that rapamycin can potentiate the tolerogenic 
properties of DC. They also reveal the potential of rapamycin-treated DC as therapeutic vectors 
of transplant tolerance.     
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1. CHAPTER ONE1     
      INTRODUCTION 
 
1.1. Dendritic cells 
1.1.1. Origins, Subsets and Functions 
Dendritic cells (DC) are a heterogeneous group of professional antigen-presenting cells (APC) 
that are essential for the immune system to recognize and react to antigens (Ag). These latest 
members of the immune system to be identified2 are recognized for their diversity and 
remarkable developmental and functional dynamism at a single cell level. It is only fitting then, 
that this dynamism is also reflected on the -ever-evolving- information acquired about their 
origins, functions and different subsets.  Currently, DC are known to induce immune responses 
to i) a variety of infectious agents, ii) tumors, iii) self Ags, prompting autoimmune reactions, and 
iv) foreign tissue Ags, instigating transplant rejection. In addition to this now well-recognized 
immunostimulatory role, DC are increasingly more acknowledged for their bridging role 
between the innate and adaptive immune responses. DC also take part in induction of central 
(thymic) and peripheral tolerance. Hence, DC appear to be critically positioned in the immune 
system where the decision of ‘if’ and ‘how’ to respond to an Ag is made.   
DC are derived from CD34+ bone marrow (BM) hematopoietic stem cells. Both common 
myeloid progenitors (CMP) and common lymphoid progenitors (CLP) can give rise to DC (2). In 
vitro, either of these progenitor populations can be induced to differentiate into DC, using 
granulocyte/macrophage colony-stimulating factor (GM-CSF) and/or fms-like tyrosine kinase 3 
                                                 
1 This chapter contains modified excerpts from reviews co-written by the author in the journals Transplantation and 
Current Opinion in Molecular Therapeutics. 
2 With the exception of epidermal Langerhans cells that were first identified in 1868 (1). 
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 ligand (Flt3L). Blood monocytes also give rise to DC when cultured with GM-CSF and 
interleukin (IL)-4, presenting a possible intermediary cell in DC development (3). In vivo, GM-
CSF or FLt3L administration results in expansion of DC. Step-by-step developmental pathways 
of different subsets of DC (discussed below), however, remains to be determined in vivo.  
In the mouse, DC in the secondary lymphoid organs are comprised of at least three different 
subsets: CD8α- classic myeloid (M)DC, CD8α+ ‘lymphoid-related’ (L)DC and CD45/B220+ 
plasmacytoid (p)DC. Whereas human counterparts of MDC and pDC exist, CD8α+ DC have not 
been demonstrated in humans. MDC are found primarily in the marginal zones of the spleen and 
the outer edges of the paracortex in the lymph nodes (4). In contrast CD8α+ DC are embedded 
deep in the T cell areas. Beside the differences in surface markers, these subsets appear to have 
different functions. These differences seem to be associated with how different antigenic stimuli 
are handled by the immune system.  Plasmacytoid DC are known to produce large amounts of 
type I interferons (IFN) (e.g. IFN-α) in response to viral infection (5), whereas bacterial cell wall 
components stimulate MDC and LDC to secrete IL-12 (6). CD8α+ cells are superior to other 
subsets in taking up dying cells, contributing to tolerance induction to self Ags (7-10). In 
addition to these well-defined lymphoid tissue populations, DC are found in virtually every 
organ, usually embedded in the interstitium, including the skin (epidermal Langerhans cells and 
dermal DC), mucosa of alimentary and respiratory tracts, reproductive system, liver, kidney and 
heart. It should be noted that, regardless of embryologic origin of the tissue they are found in, all 
DC (dendritic leukocytes) are BM-derived.    
The nature of the response initiated by DC is determined mainly by their differentiation stage, 
termed as maturation. Maturation is a complex process of end-stage DC differentiation, entailing 
several important changes in their phenotype and function (Figs. 1 & 2). When freshly-isolated 
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 from in vivo sources, or in the early stages of in vitro differentiation, DC are immature. In the 
immature state, DC have the ability to capture Ags through a variety of mechanisms. They take 
up soluble Ags by means of micropinocytosis and receptor-mediated endocytosis, and particulate 
Ags by phagocytosis. Despite the similarities with macrophages in the Ag uptake mechanisms, 
immature DC differ from the former in several ways: DC are up to four times more efficient than 
macrophages in micropinocytosis (11), presenting a quantitative advantage; and Ags taken up by 
receptor-mediated endocytosis by DC are directed to the major histocompatibility complex 
(MHC) class II processing pathway, as opposed to lysosomes for destruction in the macrophages, 
representing a qualitative advantage (12). Ag uptake is almost always followed by initiation of 
DC maturation that increases the efficiency of DC to present the Ag. During maturation, DC 
upregulate surface expression of MHC and T cell costimulatory molecules, and increase 
production of inflammatory cytokines such as IL-12, all leading to an enhanced 
immunostimulatory capacity. Maturation also leads to a major shift in chemokine receptor 
expression by DC, such that the Ag-bearing DC traffic to the T cell areas of the lymph nodes 
where T cell priming occurs. This localization is associated with upregulation of CCR7 (13) and 
downregulation of CCR5 that mediates chemoattraction of the immature/semi-mature DC to the 
inflammatory sites, where Ag encounter takes place (14). Therefore DC are uniquely well-
equipped to recognize, take up and convey Ags -especially those that are pathogen-associated, to 
T cells to induce an immune response. With these properties, DC are now regarded as the 
sentinels of the immune system. Their role, however, is not limited to inflammatory situations. In 
the steady state, DC continuously scavenge for self and non-self Ags. Uptake of apoptotic cells 
in the quiescent state by DC triggers CCR7 upregulation without stimulating maturation (15). 
Presentation of Ags by the immature DC leads to induction of unresponsiveness of the 
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 corresponding T cells to subsequent antigenic challenge (16), preventing autoimmune reactions 
that would occur otherwise. Therefore DC maturation is a key control mechanism whereby the 
appropriate immune response to an Ag is initiated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Morphology and ultrastructure of immature and mature murine BM-derived DC 
Immature DC possess short, blunt prolongations (A), a round nucleus with prominent nucleoli, 
multiple cytoplasmic vesicles, mitochondria, few lysosomes (C), and typical ‘veils’ (E). After 
maturation, CD86+ DC show typical dendritic morphology, with eccentric, indented nuclei (B, 
D) and a veiled surface with delicate filamentous projections with knob-like tips (F, arrow). (A-
B) May-Grunwald-Giemsa. (C-D) TEM x6000 (E-F) SEM x3500. Bar, 5µm. Copyright 
American Society of Hematology, used with permission. 
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Figure 2. Immature and mature BM-derived DC function. 
(A) FITC-Dextran and FITC-Albumin uptake by murine CD11c+ bead-sorted CD86- (immature) 
and CD86+ (mature) C57BL/10 mouse BM-derived DC. Only immature DC internalized FITC-
Dextran and FITC-Albumin at 37ºC, a phenomenon downregulated at 0 ºC. Results are 
representative of three independent experiments. (B) Allostimulatory activity of γ-irradiated, 
FACS-sorted immature (closed triangles) or mature DC (open triangles), assessed using C3H 
splenic T cells as responders. The MLR stimulatory activity of freshly isolated allogeneic (B10; 
open circles) or syngeneic (C3H; closed circles) bulk spleen cells is also shown. Copyright 
American Society of Hematology, used with permission. 
 
 
 
 
Several distinct types of stimuli lead to DC maturation. Thus, maturation can be induced by 
inflammatory cytokines (IL-1, IL-4, tumor necrosis factor [TNF]-α and IFNγ) or microbial 
constituents (lipopolysaccharide [LPS], unmethylated CpG oligonucleotides). The latter are 
recognized by DC through pattern recognition receptors (PRR). PRRs are evolutionarily-
conserved receptors of the innate immune system, that detect microbial pathogen-associated 
molecular patterns. Both human and murine DC express numerous PRRs, including Toll-like 
receptors (TLR), C-type lectins and mannose receptors (4). Among these, TLR are the best 
characterized, and at least 10 different TLR have been demonstrated in DC. DC can recognize 
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 Gram(+) bacterial wall peptidoglycans  by TLR2, Gram(-) bacterial LPS by TLR4, flagellins by 
TLR5 and unmethylated CpG motifs of bacterial DNA by TLR9. Viruses are detected by TLR3 
(double-stranded RNA), TLR7 (single-stranded viral DNA) and TLR9. Expression of these 
receptors varies with DC subset and maturation status. Human monocyte-derived immature DC 
express TLR1, 2, 4 and 5, all of which are downregulated upon maturation (17). In the mouse, all 
splenic DC subsets express TLR1, 2, 4, 6, 8, 9. Interestingly, both human and murine pDC lack 
TLR3 expression, but can detect viruses effectively through TLR7 and 9, and secrete high 
concentrations of type I IFNs during viral infection. Taken together, DC, by virtue of maturation 
through TLR, appear to be a major link between innate and adaptive immune responses. Apart 
from the cytokine and microbial ligands, several other stimuli in the inflammatory 
microenvironment can drive DC to maturation. Necrotic cells -possible by release of heat shock 
proteins (18) or high mobility group box protein 1 (HMGB1) (19), and CD40 ligand (CD154) 
expressed on activated T cells, induce DC maturation. The latter accounts for an important 
feedback mechanism, as ligation of CD40 on T cells stimulates their proliferation (20).  
 
1.1.2. DC in Transplantation 
1.1.2.1. DC as instigators of transplant rejection 
To understand the critical role of DC in transplant rejection (or survival), it is important 
to point out the mechanisms by which host T cells recognize the graft as ‘foreign’. 
Allorecognition occurs through two distinct pathways; direct and indirect. Although programmed 
in the thymus to recognize only self MHC molecules, 1-10% of mature T cells in the periphery 
can respond to intact allogenic MHC molecules directly (21), presumably due to homology in 
either the MHC molecule or the peptide presented in the peptide-binding groove. This direct 
recognition leads to activation of multiple T cell clones, resulting in a high frequency T cell 
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 response against the graft (22, 23). By contrast, a much smaller fraction of T cells recognize 
foreign MHC Ags when these are internalized, processed and presented on the recipient APC 
though self MHC. Hence, this ‘indirect’ pathway of allorecognition resembles the recognition of 
any given Ag in the periphery. Indeed, only <0.01% of all T cells react to a given autoAg (24) 
and <1% of reactive T cells recognize alloAgs presented indirectly (25). Although other cell 
types may contribute to activation of T cells through either pathway, donor-derived (direct) and 
host DC (indirect) are the main instigators of alloreactive T cell activation, because i) they 
possess ample amounts of MHC for recognition, ii) are equipped for efficient Ag-presentation, 
and iii) unlike other cells, are capable of providing necessary costimulation (signal 2). 
Accordingly, in a rat renal transplant model, restoration of donor DC causes rejection of 
otherwise permanently accepted donor passenger leukocyte-depleted grafts (26). Recent 
evidence suggests that these two pathways are not mutually exclusive, and interactions occur 
between them: first, in a mouse cardiac transplant model where donor DC can only provide 
MHC but not costimulation, ‘in trans’ costimulation by the host DC was shown to mediate acute 
rejection (27). Second, DC can acquire intact allogeneic MHC on their cell surface and present 
these to T cells in vitro or in vivo, -this has been termed the ‘semidirect pathway’ by Lechler’s 
group (28). Strikingly, DC are the main players in either case. It is also known that indirect 
alloreactivity regulates, negatively or positively, direct activation of T cells (29-31).  
The direct pathway was long thought to be the central mechanism instigating allograft 
rejection.  However, it is now widely accepted that the direct pathway mediates mainly early 
(within the first several months post-transplant) alloimmune responses, whereas the indirect 
pathway contributes to chronic rejection (32).  This concept is based on several studies that have 
demonstrated that direct alloreactivity diminishes with time from transplant, as donor DC are 
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 depleted. These observations, performed on human organ recipients, have been made for a 
variety of organ grafts (renal, cardiac and lung transplants) and show that, the indirect pathway 
response increases over time with increased frequencies of T cells with indirect specificities (33-
37). In the mouse model, T cells reactive to single self-restricted allopeptides (i.e. the indirect 
pathway) mediate rejection of skin grafts with characteristic chronic, fibrotic changes (38). In 
human lung transplant recipients, there is a strong correlation with chronic allograft rejection and 
development of indirect alloreactivity against donor MHC class I or class II peptides (33, 34).  In 
addition, there is increasing evidence that development of humoral immunity (de novo donor-
specific anti-HLA antibodies) is strongly associated with chronic rejection (39). It should be 
noted, however, that the indirect pathway is not merely a ‘late’ response, as indirect recognition 
by itself can induce acute rejection of skin grafts in mice (40-42), depending presumably, on the 
extent of donor/recipient MHC mismatch.  
 
1.1.2.2. DC as a therapy for transplant rejection 
The concept of cell therapy in human organ transplantation dates back to the original 
studies demonstrating the beneficial effect of blood transfusion before clinical renal 
transplantation (43). With the advancement of knowledge in DC biology and their role in the 
transplant rejection, it is now thought that the tolerogenic effect of blood transfusion may be due 
mainly to DC (44). In parallel with the initial characterization of rejection as a result of 
predominantly the direct pathway, the tolerogenic potential of donor (as opposed to recipient) 
DC in transplantation was examined first. Our group first demonstrated that intravenous (i.v.) 
administration of in vitro-propagated, donor-derived, immature MDC, seven days prior to 
transplantation, resulted in significant prolongation of murine pancreatic islet or cardiac graft 
survival in the absence of immunosuppression (45, 46). Since these original observations, 
8 
 immature donor DC infusion has been shown to prolong solid organ transplantation survival, in 
some cases indefinitely, in different rodent models (47-49). By contrast, studies using recipient 
DC as part of a therapeutic regimen to prevent transplant rejection have been limited, until 
recently.  Prolongation of cardiac or pancreatic islet graft survival in anti-lymphocyte serum 
(ALS)-pretreated rats after i.v. infusion of immunodominant donor class I MHC peptide-pulsed 
recipient DC (50, 51) remain the only such reports in the literature.      
 
 
1.1.3. DC and tolerance induction 
Although recognized initially solely for their potential in instigating immune responses, 
the role of DC in tolerance is now well-documented. Over the past two decades, DC have been 
demonstrated to induce both central and peripheral tolerance in animal models, as well as in 
humans. The first evidence regarding DC tolerogenicity was the establishment of their roles in 
generation of intrathymic self-tolerance (52, 53). The CD8α+ thymic DC mediate negative 
selection of developing T cells in the thymic medulla (54). This process constitutes an important 
central checkpoint against development of self-reactive T cells. Neonatal intrathymic injection of 
Mls (minor lymphocyte-stimulating locus)-incompatible spleen or thymic DC can induce 
tolerance via T cell clonal anergy (55), -defined conventionally as T cell receptor (TCR)-
mediated inactivation of certain potential responses, in the absence of suppressor cells or 
inhibitory cytokines (56).  Similar results have been reported in BM chimeric and transgenic (tg) 
mice (57, 58).  Intrathymic inoculation of alloAg results in tolerance and this appears to be 
dependent on thymic DC (59). Furthermore, BM-derived host MDC, pulsed with allopeptide, 
and injected intrathymically, can induce organ or pancreatic islet transplant tolerance in ALS-
conditioned hosts (60, 61). 
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  DC are also involved in the maintenance of peripheral tolerance (62-64). There is ample 
evidence that the presentation of peripherally-derived Ag by DC within secondary lymphoid 
tissue is not only effective for T cell priming, but also for the induction of T cell tolerance to 
self-Ags expressed exclusively by peripheral (extralymphoid) tissues (65, 66). Initially assigned 
to the CD8α+ LDC, this immunoregulatory function is now believed to be possessed also by 
MDC (66). Splenic CD8α+ LDC are found in T cell areas of murine lymph nodes and they 
express high levels of MHC class II/self peptide (62, 64). They kill CD4+ T cells via Fas 
(CD95)-mediated apoptosis (67) and exhibit tolerogenic activity in vivo (68). In the eye, an 
immune privileged organ, apoptotic cells enter the circulation and are captured by splenic CD8α+ 
CD11c+ LDC, which are responsible for tolerance induction when these apoptotic cells are 
coupled to a model Ag (trinitrophenyl) (69, 70). In contrast to MDC, mouse CD8α+ LDC lack 
the myeloid marker CD11b, and express high levels of the multilectin receptor CD205. In mice, 
CD8α- MDC induce T cell proliferation without concomitant cytokine (IL-2, IL-3, IFN-γ, GM-
CSF) production (63, 71).  Based on these properties of CD8α+ LDC, speculation arose that 
CD8α+ LDC and MDC were specialized for induction of tolerance and immunity, respectively 
(72). MDC, however, have also been shown to induce tolerance, in several animal models. For 
instance, i.v. inoculation of immunodominant peptide-pulsed MDC of host origin induces long 
term, Ag-specific survival of pancreatic islet transplants in a rat model (51).  Furthermore, 
influenza matrix peptide- or keyhole limpet hemocyanin-pulsed immature autologous MDC 
induce tolerance to these Ags in healthy human volunteers (73).  In mice, adoptive transfer of 
Ag-pulsed CD8α+ LDC or MDC appears to induce predominant Th1 or Th2 responses, 
respectively (74, 75). The converse has been reported for human (plasmacytoid) DC2 and 
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 (monocytoid) DC1 in vitro (76). Thus, it appears that either subset can induce tolerance, 
depending on the experimental conditions, animal models, species and the Ag.  
 Apart from the above-mentioned differences in DC subsets, the capacity of DC to 
stimulate or suppress immune reactivity may depend on their level of maturity, the route of their 
in vivo administration, the temporal relationship between their administration and that of Ag, the 
number of cells injected, the amount and physical condition (soluble or particulate) of Ag 
presented by DC.  Thus, DC loaded with low doses of tumor Ag enhance tumor rejection, while 
those loaded with high doses, or injection of large numbers of tumor Ag-pulsed DC, inhibit their 
anti-tumor effect (77).  BM-derived MDC can prolong skin allograft survival when administrated 
via the portal vein, but not after i.v. immunization (78). By contrast, subcutaneously (s.c.)-
injected, trinitrobenzenesulphate (TNBS)-pulsed DC sensitize for contact hypersensitivity in 
syngeneic recipients, whereas i.v. injected DC do not (79). Murine immature MDC, infused 
systemically, can prolong cardiac or islet allograft survival, whereas mature MDC from the same 
donor strain, accelerate rejection (45, 46). Similarly, in the mouse model where LDC are 
responsible for cross-tolerization to apoptotic cell-bound Ag, immunity rather than tolerance 
develops if agonistic CD40 mAb is administered concomitantly, indicating that the fate of the 
immune response depends on the level of maturity of DC. In the same system, tolerance 
induction ensues when CD40/CD40L interaction is blocked with anti-CD40 mAb, keeping DC at 
an immature stage (70).  
Several mechanisms by which DC regulate immune reactivity have been proposed over 
the last few years: induction of T cell anergy and/or apoptosis, Th1/Th2 immune deviation and 
induction of regulatory T cell (Treg) subsets (80-85). These mechanisms, at large, concur with 
those that are widely accepted for the induction of tolerance (86). Evidence for each mechanism 
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 is summarized below. It should be noted that the mechanisms postulated may not be mutually 
exclusive, and may collectively contribute to tolerance induction. 
 
1.1.3.1. Induction of T cell anergy or apoptosis 
DC maturity, as discussed above, is an important determinant of the immune response generated 
against the Ags presented by DC. Several groups have demonstrated that when maturation of DC 
is suppressed by blockade of costimulatory molecule expression (87) or by exposure to anti-
inflammatory cytokines (IL-10 and transforming growth factor [TGF]-β) (88-91), they induce 
Ag-specific T cell hyporesponsiveness. This is in accordance with the current model of tolerance 
induction that postulates that T cells, when activated in the absence of Signal 2, become anergic 
and therefore unresponsive to further stimuli. In the quiescent state, immature DC convey self 
Ag and induce T cell anergy/deletion in the periphery, resulting in tolerance to the particular self-
Ag (92). In a similar fashion, presentation of tumor-associated and self-Ag peptide by DC can 
induce T cell anergy in vivo (93). Interestingly, in mice, intrathymic injection of soluble Ag 
(ovalbumin; OVA), leading to interaction with thymic DC (presumed LDC), results in peripheral 
T cell anergy (94), possibly mediated by DC migrating from the thymus (95).  
 DC have also been shown to promote T cell apoptosis, through various death-associated 
molecules. Thus, Fas ligand (FasL; CD95L) (67, 96) or nitric oxide (NO) (97) expressing DC 
can promote activation-induced T cell death. FasL-Fas pathway appears to be important in the 
DC-induced apoptosis of alloreactive T cells, following blockade of the  B7/CD28 pathway by 
CTLA4Ig (96). DC expressing influenza virus hemagglutinin (HA) can induce tolerance in the 
periphery by inducing anergy and deletion of naïve mature T cells (98). 
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 1.1.3.2. Selective activation of Th2 cells (immune deviation) 
Immune deviation (skewing of T cells toward the Th2 type) is another mechanism that has been 
shown to underlie tolerance induction. Several groups have shown that DC can induce immune 
deviation in autoimmune disease and transplant models. DC that are rendered incapable of IL-
12p70 synthesis have been shown to activate Th2 cells selectively (99). CTLA4Ig-pretreated 
splenic DC, when pulsed with myelin basic protein (MBP) and infused systemically, block 
development of experimental allergic encephalitis (EAE) in rats. (100). The protective 
mechanism in this model appears to be immune deviation, as immunohistology of the central 
nervous system demonstrates almost complete inhibition of IL-2 and IFNγ, with upregulation of 
IL-4 and IL-13 production (100). Thus, tolerogenic DC, obtained by blocking costimulatory 
molecule expression with soluble protein, appear to lose their capacity to induce Th1 
responses/immunity, and can selectively activate Th2 cells.  IL-10, a signature cytokine for Th2 
response, appears to provide positive feedback to DC, as it skews the Th1/Th2 balance to Th2 
cells by blocking IL-12p70 synthesis by DC (88).  Accordingly, DC of any origin/lineage can 
favor stimulation of either Th1 or Th2, mostly depending on the nature of the stimulus, 
experimental and local environmental conditions (101). For instance, in the presence of high 
dose Ag, both MDC and pDC induce Th1 development, whereas low Ag dose favors Th2 
development regardless of the DC subset (102). In contrast to several reports demonstrating the 
beneficial effect of immune deviation in different autoimmune disease models, the role of this 
mechanism in transplant tolerance remains controversial (103, 104). The graft prolongation 
observed in some models is presumably due mainly to the dampened Th1 response, since Th2 
cells are equally effective in the allograft rejection process (105, 106). 
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 1.1.3.3. Induction of Treg Cells 
Since the recent repopularization of the concept of ‘extrinsic’ T cell suppression by Treg cells, 
the role of DC in the induction of these regulatory cells is increasingly being recognized. 
Strikingly, this role entails promotion of not only a single type, but a variety of Treg cells in 
different models (107, 108). In vitro, repeated stimulation of human naïve T cells with allogeneic 
immature DC results in IL-10 producing CD4+ T cell population with regulatory capacity (109). 
Moreover, in humans an Ag-specific, IL-10 secreting CD8+ T cell subset can be induced by 
immature, Ag-pulsed DC (73). In the mouse, a murine liver-derived B cell-like DC 
(CD205+B220+CD19-) can induce allogeneic T cells with a cytokine profile resembling Tr1 cells 
(110). Based on these and similar studies, a paradigm has evolved over the last several years 
whereby DC maturation is a control point for the generation of effector (by mature DC) vs. 
regulatory T cells (by immature DC) (111). This paradigm, however, has been challenged 
recently by reports that demonstrate induction of Treg cells by mature myeloid (112) and 
plasmacytoid-like (CD11clowCD45RBhigh) DC (113) in mouse. Taken together, these 
observations provide evidence that DC can promote development of Treg cells and potentially be 
used for therapy in transplantation, since Treg cells have been repeatedly isolated from tolerated 
allografts and draining lymphoid tissues in animal models (114).   
 
 
1.1.4. DC plasticity 
With the development of culture methods that allowed researchers to generate large numbers of 
DC in vitro, much information has accumulated in recent years about their functions under 
different environmental conditions. These observations have also revealed the remarkable 
plasticity of DC. This plasticity allows DC generated from a single source to be modified to 
either boost immunity -as in cancer and infectious diseases, or induce tolerance -in autoimmunity 
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 and transplantation. Different approaches to ‘program’ DC for tolerance induction include 
genetic (transgene insertion), biologic (differential culture conditions, anti-inflammatory 
cytokine exposure) and pharmacologic manipulation (23, 115) (Fig. 3). 
 
 
 
Figure 3. Strategies for generating regulatory/tolerogenic DC. 
Regulatory DC can be designed by biological (differential culture conditions), pharmacological 
or genetic modification of in vitro generated DC. These approaches allow researchers to tailor 
the tolerogenic properties of DC, exploring their use for immunotherapy in immune-mediated 
conditions. Modified from (115). 
 
 
1.1.4.1. Biologic modification of DC 
Presently, DC, particularly of the myeloid subset, can be generated from either BM precursors 
(BMDC) or human peripheral blood monocytes (MoDC). Both approaches use combinations of 
GM-CSF and IL-4 as the baseline DC growth factors. During the past decade, several different 
culture methods have been introduced to produce DC capable of regulating T cell responses. 
When cultured in low-dose GM-CSF, in the absence of IL-4, BM precursors give rise to 
immature DC, which can prolong allograft survival, when infused into recipients prior to 
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 transplant (46, 48). Both human MoDC and BMDC acquire regulatory functions when cultured 
with IL-10 (88-90) and/or TGF-β1 in addition to GM-CSF and IL-4 (116, 117). These DC induce 
T cell anergy through either the direct or the indirect pathway (118), and show protective effects 
when infused 2 days after BM transplantation in mice. Interestingly, the regulatory action of 
these DC is twofold: they inhibit mature DC-mediated T cell stimulation and induce generation 
of CD4+CD25+ Treg cells constitutively expressing CD152 (CTLA-4). Even if these two 
mechanisms may not be mutually exclusive, it is important to note that Treg cells can be 
generated by IL-10-conditioned regulatory DC in the presence of mature DC. Murine BMDC 
matured with short-term (4 h) TNF-α treatment become poor producers of the inflammatory 
cytokine IL-12, despite their mature phenotype. These DC induce IL-10-producing CD4+ T cells 
and prevent EAE in the mouse model (119). Together, these studies underscore the importance 
of stably immature DC that fail to produce Signal 2 (i.e. costimulation) or Signal 3 (i.e. 
inflammatory cytokine secretion), in promoting T cell tolerance.  
When prostaglandin E2 (PGE2) is used (as a part of maturation stimuli) in DC cultures, the 
cells become severely impaired in their ability to produce IL-12p70 (99, 120). These DC are 
refractory to further stimuli, and promote selective Th2 activation. Like PGE2, PGD2 inhibits IL-
12 secretion by both BMDC and MoDC, and promotes a type 2 response. (121, 122). Similarly, 
addition of adenosine (123) and Atrial Natriuretic Peptide (ANP) (124) into DC cultures 
promotes generation of DC with ability to selectively induce Th2 activation. MoDC stimulated 
with adenosine upregulate expression of MHC and costimulatory molecules, but become poor 
producers of IL-12p70, TNF-α and CXCL10 (ligand for CXCR3, which is preferentially 
expressed by Th1 cells) in response to LPS. Adenosine also enhances LPS-induced IL-10 and 
CCL17 (ligand for CCR4, which is expressed preferentially by Th2 cells) secretion by DC.  
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 1.1.4.2. Genetically engineered DC 
Their unique role in either generating or regulating the immune responses, coupled with the 
potential to deliver the desired gene products locally makes DC highly attractive vectors for all 
immunotherapeutic approaches. Significant findings have been reported recently regarding 
genetically modification of DC to enhance their tolerogenic potential. One of these 
immunoregulatory transgenes, IL-4, has been introduced successfully into DC. IL-4 is a Th2-
driving cytokine that inhibits IL-2 and IFNγ production by Th1 cells and inflammatory cytokine 
production by macrophages. Hence, DC producing IL-4 provide potential in situations where 
selective Th1 silencing is required. DC transfected adenovirally to express IL-4 prevent the onset 
of diabetes in non-obese diabetic (NOD) mice and alter the Th1:Th2 cytokine ratio in favor of 
the latter in the pancreas (125). These findings support earlier reports showing inhibition of 
murine collagen-induced arthritis (CIA) by IL-4-transduced DC (126, 127). In contrast, research 
from our group has revealed that IL-4-transduced DC produce increased amounts of IL-12, 
become better stimulators of T cells and accelerate graft rejection when infused 7 days prior to 
transplantation. Combined, these reports illustrate the distinct responses to the same approach to 
DC manipulation in different animal models and underline the differences between syngeneic 
(i.e. autoimmunity) vs. allogeneic (i.e. transplantation) systems.  In a similar manner, DC 
transduced to express FasL have been reported to improve pre-established CIA after a single i.v. 
infusion (128), whereas they may induce rejection of skin grafts after s.c. injection (129), 
demonstrating the importance of their route of delivery. Indolamine 2,3-dioxygenase (IDO), an 
enzyme involved in catabolism of tryptophan, has lately become the focus of attention due to its 
role in controlling autoimmunity. When MoDC are made to overexpress IDO, they lose their T 
cell allostimulatory capacity, presumably due to increased T cell death exerted by tryptophan 
catabolites (130). At present, it is not clear if this is the main mechanism of immunoregulation by 
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 IDO-expressing DC. Nevertheless, these in vitro effects merit exploration in transplant and 
autoimmunity models. In a different approach, attempting to interfere with their maturation by 
inhibiting NF-κB, MoDC transduced to overexpress IκBα were found to lose their stimulatory 
activity for Ag-specific T cells in vitro (131). Interestingly, the mechanism underlying this effect 
was not anergy, but increased T cell apoptosis. When IL-12 production by DC is targeted by 
small interfering (si)RNA technology, IL-10 production is significantly upregulated and these 
DC promote Th2 polarization, both in vitro and in vivo (132).  In the rhesus monkey, adenoviral 
transduction of TGF-β1 in MoDC inhibits their T cell allostimulatory capacity and makes them 
capable of abrogating Ag-specific immune responses induced by mature DC (133).   
1.1.4.3. Pharmacologic modification of DC 
The onset of increased popularity in altering DC function by means of pharmacologic 
intervention coincides with interest in influence of immunosuppressive drugs on DC. Although 
most of the immunosuppressive agents used in clinics owe their approval to earlier studies 
performed predominantly on lymphocytes, their potent effects on DC have now been well-
established. Once studied extensively, this approach has the potential of using the 
immunosuppressive agents in a more selective, specifically targeted way, by means of 
manipulated DC. In addition to the immunosuppressives, a wide variety of pharmacologic agents 
(e.g. Vitamin D, Aspirin, N-acetyl cysteine) are being investigated for their impact on DC. In 
these studies, typically DC are either generated in vitro and exposed to the agent of interest for 
different durations, much as the differential culture methods discussed above, or they are isolated 
freshly from animals after in vivo administration of the agent.  
Cyclosporine A (CsA) has been shown to inhibit the maturation and allostimulatory 
capacity of mouse MDC, by inhibiting NF-ĸB translocation (134). CsA also impairs IL-6 and IL-
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 12 production by DC, and DC-triggered production of IFNγ, IL-2 and IL-4 by T cells in the bi-
directional DC-T cell system (135). By contrast, human MoDC appear resistant to the inhibitory 
effects of CsA on their maturation and allostimulatory capacity (136). Similarly, another 
calcineurin inhibitor, FK506, has been reported to have heterogenous effects on DC maturation, 
depending on the stimuli used to trigger DC maturation in each experimental system (137). 
Glucocorticoids inhibit LPS- or CD40L-induced DC maturation, and DC production of IL-12 
and TNF-α. DC exposed to dexamethasone fail to prime Th1 cells efficiently, and repeated 
stimulation of T cells with these DC generates IL-10-producing Treg cells (138). Sanglifehrin, a 
novel immunophilin-binding immunosuppressive agent, targets DC more selectively by 
suppressing IL-12 and TNF-α production without affecting differentiation, maturation and cell 
viability (139). In addition to these immunosuppressant agents, several other pharmacologic 
agents with anti-inflammatory properties have been shown to target DC function (137). Hence, 
Vitamin D (140), aspirin (141), N-acetyl cysteine (142), glatiramer acetate (143) and BAY (an 
NF-κB translocation blocker) (144) have all been shown to inhibit DC maturation, stimulatory 
function and/or their ability to produce IL-12. However, the advantage of using the above-
mentioned classic immunosuppressives to ‘program’ tolerogenic DC lies in the fact that this 
approach provides a relatively safe passage into pre-clinical large animal (non-human primate) 
and –potentially- clinical trials, as these agents currently constitute the mainstream therapy for 
graft rejection.   
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 1.2. Rapamycin 
1.2.1. Clinical development 
Rapamycin, a macrolide antibiotic pro-drug derived from Streptomyces hygroscopicus, was first 
isolated from a soil sample taken from Easter Island (Rapa Nui) in 1973, during a discovery 
program for new antimicrobial agents (145). It was first recognized for its potent antifungal 
actions. Shortly after, however, its immunosuppressive properties were documented by Dr. Suren 
Sehgal and his collegues at the Ayerst Laboratories, where the drug was first characterized. In 
the first animal experiments, rapamycin was demonstrated to inhibit the development of adjuvant 
arthritis and EAE in rodent models (146). It was later shown to prevent onset of type-1 diabetes 
in NOD mice, prolong survival in MRL/l mice (model of systemic lupus erythematosus [SLE]) 
and inhibit incidence and severity of polyarthirits in CIA mouse (147). Rapamycin’s 
antirejection activity in organ transplantation was first described by Sir Roy Calne in rats 
receiving heart and in pigs receiving kidney grafts (148). After numerous single- and multi-
center clinical trials, rapamycin was approved by the FDA in 1999 to be used for kidney 
transplant rejection, as part of a combination therapy.  
 
1.2.2.  Mechanism of Action  
Similar to the earlier discovered immunosuppressant FK506, rapamycin forms a complex with 
the intracellular immunophilin FK506 binding protein (FKBP12). Unlike FK506, however, 
rapamycin does not inhibit calcineurin phosphatase activity. Instead, the rapamycin-FKBP12 
gain-in-function complex inhibits the function of the serine/threonine kinase mammalian target 
of rapamycin (mTOR), a central effector protein that is shared by several signal transduction 
pathways (Figure 4) (145). The TOR protein is highly conserved from yeast to mammals. It 
controls cap-dependent translation initiation by phosphorylating eukaryotic translation initiation 
factor 4E (eIF4E)-binding protein 1 (4E-BP1). In the unphosphorylated form, 4E-BP1 binds and 
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 inhibits activation of eIF4E. Phosphorylation by TOR promotes dissociation of 4E-BP1 and 
eIF4E (149, 150). When released, eIF4E, along with other initiation factors, forms the eIF4F 
complex. This complex is required for translation initiation of 5’-capped mRNAs in eukaryotes. 
TOR also phosphorylates -either directly or indirectly- and activates the ribosomal p70 S6 kinase 
(S6K). S6K activation is associated with translation of 5’ terminal oligopyrimidine tract (TOP) 
mRNAs, which exclusively encode for proteins involved in translational machinery (all 
ribosomal proteins, elongation factors, and the poly-A binding protein). Activation of eIF4e and 
S6K is induced by serum, growth factors and insulin, and blocked by rapamycin. A recently-
identified adaptor protein named regulatory associated protein of TOR (raptor) binds to TOR and 
its two downstream effectors S6K and 4E-BP1. It appears that, at least in vitro, raptor is required 
for efficient phosphorylation of 4E-BP1 and S6K (150). Rapamycin disrupts the mTOR-raptor 
complex, thereby preventing downstream pathways (151). Complete inhibition of TOR by 
rapamycin causes only partial inhibition of TOP mRNA translation (152), but blocks eIF4F-
mediated cap-dependent translation initiation (153). Despite comparatively limited suppression 
of protein translation, due to their selective properties, inhibition of TOR leads to an arrest in cell 
growth, both in size (by mimicking nutrient deprivation) and in number (by inhibition of cell 
cycle). Thus, activated eIF4E and S6K cooperate to control cell size (154) and to promote cell 
cycle progression (155). Selective translation of mRNAs encoding growth factors such as the 
fibroblast growth factor (FGF) and the vascular endothelial growth factor (VEGF) may also be 
prompted by eIF4E, accounting for another mechanism whereby TOR inhibition leads to the 
arrest of cell growth (156).  
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Figure 4. TOR is a central regulator of cell growth and proliferation in response to 
environmental and nutritional conditions. 
TOR signaling is regulated by growth factors, amino acids, ATP and O2 levels; second 
messengers (for example, phosphatidic acid); and, possibly, mitochondrial stress. Signaling 
through TOR seems to regulate several downstream pathways that impinge on cell-cycle 
progression, translation initiation, transcriptional stress responses, protein stability and survival. 
Dashed lines indicate pathways that are best described in yeast. ATP, adenosine triphosphate; 
ASK1, apoptosis-signal-regulating kinase 1; S6K1, ribosomal p70 S6 kinase 1; eIF4E, 
eukaryotic translation initiation factor 4E; 4E-BP1, eIF4E-binding protein 1. Figure taken from 
(149). 
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 1.2.3. Immunosuppressive and tolerogenic effects 
The immunosuppressive effects of rapamycin are associated mainly with inhibition of T cell 
activity (145). This inhibition occurs through several distinct mechanisms. During T cell 
activation, ligation of CD28, the best described costimulatory receptor on T cells, results in 
activation of the transcription factor Rel-1, a CD28 response element-binding factor. In the 
absence of CD28-mediated costimulation, Rel-1 is sequestered in the cytoplasm by the 
regulatory protein IκBα. Ligation of CD28 leads to phosphorylation and subsequent degradation 
of IκBα, allowing Rel-1 translocation to the nucleus. Downregulation of IκBα is blocked by 
rapamycin, therefore inhibiting CD28-mediated transcription in T cells (157). In addition, 
rapamycin inhibits IL-2-mediated T cell mitogenesis by inhibiting activation of S6K and cyclin-
dependent kinase (cdk) through elimination of the cdk inhibitor protein p27kip1 (158), hence 
blocking their entry into S phase (159). By and large, rapamycin prevents T cell proliferation in 
response to a variety of stimuli, including mitogens, cytokines and CD3-CD28 crosslinkage, in 
both humans and rodents (160-163). Stimulation of T cell clones in the presence of rapamycin 
leads to an anergic state (164). Furthermore, in the anergic T cell clones, reversal of anergy by 
IL-2 is blocked by rapamycin (165). Apart from these well-defined potent suppressive activities 
on T cells, rapamycin also inhibits B cell proliferation (166) and differentiation into 
immunoglobulin (Ig)-producing plasma cells (167); spontaneous and FGF-mediated proliferation 
of endothelial cells and fibroblasts (168), and basic (b)FGF and platelet-derived growth factor 
(PDGF)-driven proliferation of vascular smooth muscle cells (169, 170) (Table 1). The latter 
effects provide rapamycin an advantage over other commonly-used anti-rejection agents in 
controlling chronic allograft rejection. In fact, rapamycin stops the progression of graft vascular 
disease (GVD) in a non-human primate model (171) and slows cardiac transplant vasculopathy 
progression in humans (172).  
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Table 1. In vitro cellular effects of rapamycin (sirolimus). 
Table taken from (145), with permission from Elsevier. 
 
 
Strikingly, rapamycin has emerged as a “tolerance-sparing” immunosuppressant in recent years. 
Currently, two lines of evidence support this paradigm. First; unlike other commonly-used 
immunosuppressive agents, rapamycin does not interfere with tolerance induction in different 
animal models (173, 174). This unique ability is attributed, at least partly, to rapamycin’s 
capacity to allow activation-induced cell death (AICD) in T cells. In mice, AICD is a crucial 
component of tolerance induction (175). Therefore, administration of rapamycin facilitates 
peripheral tolerance in mice (174). Rapamycin blocks the proliferative effects of IL-2 on T cells, 
without interfering with its pro-apoptotic actions (176). Second, rapamycin acts synergistically 
with costimulation blockade in animal models, a unique action that is not shared by the 
conventional immunosuppressive agents like corticosteroids and FK506, which have a negative 
impact on the efficacy of costimulation blockade (177).  
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 SCOPE OF THIS THESIS 
As organ transplantation has become a common practice around the world, transplant recipients 
on life-long immunosuppression, with compromised defenses against life-threatening infections 
and cancers, have increased in number. There is a clear and urgent need to better understand the 
mechanisms underlying allograft rejection, and to develop strategies that promote the induction 
of Ag-specific transplant tolerance. Until recently, the influence of commonly-used 
immunosuppressive agents on DC have been ignored, due mainly to their well-known, potent 
anti-lymphocyte activities. In this thesis, we have investigated systematically the inhibitory 
activities of rapamycin on events leading to T cell activation, focusing on the functional 
immunobiology of DC. In Chapter Two, we present our findings regarding the impact of 
rapamycin on mouse BM-derived DC (BMDC), using mainly in vitro approaches. In Chapter 
Three, we expand our observations to DC freshly-isolated from (both steady-state and growth 
factor-mobilized) rapamycin-treated mice. Here, along with the in vivo/ex vivo analyses, we 
employ adoptive transfer of DC to naïve animals in order to evaluate their tolerogenic function. 
Based on our findings in these two chapters, in Chapter Four, we examine the impact of 
exposure of BMDC to rapamycin on their subsequent capacity for alloAg presentation and 
tolerance induction via the indirect pathway. We have also tested the efficacy of pre-transplant 
infusion of these cells in a clinically-relevant transplant model in order to evaluate their potential 
as therapeutic vectors.     
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 2. CHAPTER TWO3 
IMPACT OF RAPAMYCIN ON IN VITRO-GENERATED DC  
 
2.1. ABSTRACT 
MDC with potent allostimulatory capacity can be generated in large numbers from BM 
precursors with GM-CSF ± IL-4 (BMDC). Given the recently-reported ‘tolerance-sparing’ 
impact of the immunosuppressant rapamycin, and the paucity of information on its impact on 
DC, here, we have investigated the effects of rapamycin on the phenotype and functions of 
BMDC. Rapamycin, in clinically-relevant doses (1-10 ng/ml), inhibited maturation and 
allostimulatory capacity of GM-CSF + IL-4 expanded DC, without interfering with their 
differentiation in vitro. These effects were strictly IL-4 dependent, and not observed when DC 
were expanded with GM-CSF alone. Studies to explore the underlying mechanism revealed that 
rapamycin suppressed surface expression of both subunits of the IL-4 receptor complex on DC. 
In addition, rapamycin inhibited macropinocytosis and receptor-mediated endocytosis by DC, 
nonetheless, in an IL-4-independent manner. These effects were not due to increased apoptotic 
cell death and by contrast, rapamycin had a protective effect against LPS-induced apoptotic DC 
death. Strikingly all these effects were mediated through FKBP12 binding and mTOR inhibition, 
as molar excess of FK506 antagonized the suppressive effects of rapamycin on DC.  
 
 
 
 
                                                 
3Data presented in this chapter is excerpted from (178) and (179). 
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 2.2. INTRODUCTION 
Rapamycin is now a commonly used immunosuppressive agent for prevention and treatment of 
transplant rejection. Owing to its broad inhibitory action on the cell cycle and protein synthesis, 
rapamycin or its derivatives are also in clinical trials for treatment of several tumors and 
atherosclerotic coronary artery disease (149). During the clinical development of rapamycin, 
much like other immunosuppressants, T cells had been considered the principal therapeutic 
targets (180). A much less studied aspect is the possible impact of rapamycin on DC, and their 
ability to present Ag to T cells prior to Ag-specific lymphocyte activation and proliferation. As 
discussed above, DC are ubiquitously distributed APC that play critical roles as initiators and 
modulators of immune responses (181). Among the most striking features underlying the 
efficiency of DC as APC is their unsurpassed capacity to take up Ags via constitutive 
macropinocytosis and mannose receptor-mediated endocytosis (11) and to subsequently process 
and present MHC-Ag complexes on their surface (181).  The capacity of DC to endocytose and 
to present Ag is under tight developmental control: immature DC are excellent at internalizing 
Ag, but express low surface MHC class II, whereas mature DC downregulate endocytotic 
activity and upregulate MHC class II and costimulatory molecules (CD40, CD80, CD86) that 
promote T-cell activation. The ability of DC to initiate an immune response depends on their 
transition from Ag-processing to Ag-presenting cells. This transition constitutes an important 
checkpoint in mounting an immune response, as immature DC not only fail to prime T cells 
effectively (87, 182), but also serve  to promote tolerance induction (46, 73, 109, 115). 
In this chapter, we have systematically investigated the influence of rapamycin on DC 
functions in vitro. For this, we used mouse BMDC generated in GM-CSF ± IL-4, that are known 
for their remarkable allostimulatory capacity (183). Our results reveal that rapamycin, while 
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 allowing DC generation from BM precursors, interferes with DC function at various levels, 
impairing immune reactivity at the earliest stages. We show that DC, when exposed to 
rapamycin in vitro, exhibit an immature phenotype and fail to stimulate allogeneic T cells. 
Strikingly, rapamycin treatment inhibits Ag uptake by DC, dissociating this important function 
from DC maturation. The inhibitory effect of rapamycin on functional DC maturation appears 
due, at least partly, to interference with IL-4 signaling. These novel insights into the action of 
rapamycin are likely to contribute to the understanding of the immunosuppressive action of this 
agent in transplantation, and aid the development of this and other agents that impact on DC 
function for the treatment of autoimmune diseases. In addition, rapamycin appears to be a good 
candidate to enhance the tolerogenic potential of DC, that could potentially be used as 
therapeutic vectors to induce tolerance.  
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 2.3. MATERIALS and METHODS 
2.3.1. Animals 
Eight-to 12-week-old C57BL/10 (B10; H2Kb) and C3H/HeJ (C3H; H2Kk) mice were purchased 
from The Jackson Laboratory (Bar Harbor, ME) and maintained in the specific pathogen-free 
Central Animal Facility of the University of Pittsburgh Medical Center. IL-4 receptor (R) α-
deficient mice (BALB/c background) (184) were obtained from the Institute for Clinical 
Microbiology and Immunology, University of Erlangen, Germany.   
 
2.3.2. Generation of BMDC 
BMDC were generated as described previously (141). Briefly, B10 BM cells were flushed from 
femurs and tibias using PBS. These cells then were cultured for 7 days in RPMI-1640 with 10% 
heat-inactivated fetal calf serum (FCS), L-glutamine, non-essential amino-acids, sodium 
pyruvate, penicillin-streptomycin, HEPES (N-2-hydroxyethylpiperazine-N'-2-ethane-sulfonic 
acid), 2- mercaptoethanol (all from Life Technologies, Gaithersburg, MD), 1000 U/ml 
recombinant (r) murine GM-CSF (Schering-Plough, Kenilworth, NJ) ± 1000 U/ml r murine IL-4 
(R&D Systems, Minneapolis, MN). 1-100 ng/ml rapamycin (Sigma, St. Louis, MO) ± 10-100 
ng/ml FK506 (tacrolimus; Prograf® for i.v. use, Fujisawa Healthcare, Deerfield, IL) was added at 
day 2. Every 2 days, 75% supernatant was replaced with fresh, cytokine-containing medium (± 
rapamycin or FK506).  On day 4, non-adherent cells were removed; on day 7, ≥50% of the non-
adherent cells expressed CD11c. 
 
2.3.3. Phenotypic analysis of DC 
DC surface Ag expression was analyzed by flow cytometry on day 7 of BM culture. Fluorescein 
isothiocyanate (FITC)-, phycoerythrin (PE)-, CyChrome-conjugated or biotinylated monoclonal 
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 antibodies (mAbs) used to detect expression of CD11c (HL3), CD40 (HM40-3), CD54 (ICAM-
1; 3E2), CD80 (16-10A1), CD86 (GL1), IAb β chain (25-9-17), H2Kb (AF6-88.5), IAd (AMS-
32.1), CD124 (Institute for Microbiology and Immunology, University of Erlangen, Germany) or 
CD132 (TUGm2), as well as isotype-matched control mAbs and Streptavidin-CyChrome, were 
purchased from BD PharMingen (San Diego, CA), unless otherwise noted. Five × 105 cells were 
blocked with 10% v/v normal goat serum (10 min; 4 °C) then stained with mAb (30 min; 4 °C). 
Appropriate isotype-matched Igs were used as negative controls. The cells were analyzed using 
an EPICS Elite flow cytometer (Beckman Coulter, Hialeah, FL).   
 
2.3.4. Mixed Leukocyte Reaction (MLR) 
For evaluation of their T cell allostimulatory activity, graded numbers of γ-irradiated (20Gy), 
immunomagnetic bead-purified B10 BMDC were cocultured with nylon-wool column-enriched 
allogeneic (C3H) splenic T cells for 72h, in a volume of 200 µl in round-bottom plates. For the 
final 18h, cells were pulsed with 1 µCi [3H]/well. The amount of radioisotope incorporated was 
determined using a β-scintillation counter. 
 
2.3.5. RNase protection assay  
The procedure adopted for RNase protection assay was performed as described in detail (185). 
Briefly, RNA was isolated from 5 × 106 snap-frozen, immunomagnetic-bead sorted DC using a 
total RNA Isolation Kit (BD PharMingen). The RNase protection assay was performed using the 
RiboQuant Multi-Probe RPA System (BD PharMingen) with 32P-UTP-labeled antisense RNA 
probes specific for CD124, CD132 and the housekeeping genes L32 and glyceraldehyde-3-
phosphatedehydrogenase (GAPDH) according to the manufacturer’s instructions. Mouse RNA 
and RNA degradation controls were included. Yeast tRNA served as negative control.  
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 2.3.6. Analysis of apoptosis  
DC were stimulated with LPS (1 µg/ml RPMI culture medium) or left without any stimuli and 
apoptosis was analyzed over time by staining of phosphatidylserine translocation with FITC-
Annexin-V in combination with the vital dye 7-AAD (BD PharMingen) according to the 
manufacturer’s instructions. Cells were co-stained for CD11c to allow specific analysis of DC by 
flow-cytometry. 
 
2.3.7. Endocytosis  
Quantitative analysis of endocytosis was performed as described (141) with minor modifications. 
Five × 105 cells were incubated with 5 µg/ml FITC-Albumin  (MW 66,000, Sigma) or 0.1 mg/ml 
FITC-Dextran (MW 42,000, Sigma) at either 37 °C or 4 °C for 60 min. Endocytosis was stopped 
by two washes in ice-cold 0.1% sodium azide/1% FCS/PBS. Cells were stained for CD11c 
(HL3), and in some experiments, for MHC class II expression (IAb β-chain, 25-9-17) as 
described (mAbs from BD PharMingen).  
 
2.3.8. Statistical analyses  
Statistical analyses were performed using Student’s ‘t’ test or the Wilcoxon rank sum test. All 
tests were performed two-tailed; P<0.05 was considered significant. Normal distribution of 
values, a prerequisite for using Student’s ‘t’ test, was established by employing the Kolmogorov-
Smirnov test.  
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 2.4. RESULTS 
2.4.1.  Rapamycin does not inhibit DC differentiation in vitro 
To investigate the impact of rapamycin on in vitro DC generation, we first compared the cell 
yield in cultures grown in the presence or absence of rapamycin. When added on day 2 of the 7-
day DC cultures, rapamycin concentrations within the human whole blood trough therapeutic 
range (186) inhibited total cell expansion in a dose-dependent manner, but did not significantly 
block the differentiation of precursor cells into CD11c+ DC as evidenced by the similar yield of 
CD11c+ DC. CD11c is a very reliable marker for murine DC (187) and is not expressed in 
significant amounts by murine macrophages (188). The decrease in total cell number was 
antagonizable by a 20-fold molar excess of FK506. Achievement of similar DC yields was due to 
consistently increased percentages of CD11c+ DC with characteristic DC morphology in the 
rapamycin-treated cultures, as observed by flow-cytometry and under the microscope, 
respectively. 
 
Figure 5. Numbers of DC are 
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BMDC were propagated for 7 days, as 
described in Materials and Methods; 
rapamycin (Rapa) was added on day 2 (± 
FK506) at the concentrations indicated. 
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were compared. Differences between 
paired cultures were assessed by two-
tailed Student’s ‘t’ test for paired samples 
(*P<0.05 vs. control). Results are 
representative of 6 separate experiments.  
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 2.4.2. Rapamycin inhibits maturation of BMDC in an IL-4 dependent manner  
As outlined in the introduction, DC maturation is an important check point by which the outcome 
of the immune reaction is determined. Thus, next we examined the impact of rapamycin on DC 
maturation. Rapamycin (1-10 ng/ml) decreased surface expression of CD40, CD80, CD86 and 
MHC class II molecules on GM-CSF+IL-4 expanded DC harvested on day 7 of culture (Fig. 
6A). Accordingly, the T cell allostimulatory activity of CD11c immunobead-purified DC was 
also markedly impaired by rapamycin in a dose-related manner, whereas the structurally-related 
macrolide immunosuppressant FK506 had no effect on DC phenotype or function (Fig. 6A, B). 
Rapamycin, when added late, at day 5 of culture, inhibited DC maturation similarly as compared 
to day 2, though to a slightly lesser extent (e.g. 57% of control DC vs. 30% of rapamycin-treated 
cells expressed MHC class II, 50% vs. 32% expressed CD86, and 47% vs. 16% expressed 
CD40); ruling out the possibilities that, i) rapamycin affects the generation of a certain DC 
subtype in culture, and ii) its inhibitory effect on DC maturation is limited to earlier stages of 
differentiation.  
Next we analyzed whether the inhibition of DC maturation by rapamycin was IL-4-
dependent, since IL-4 promotes DC maturation (87, 189) and performed similar experiments in 
the absence of IL-4. For this, DC were generated from BM precursors with GM-CSF alone, in 
the presence or absence of rapamycin. Generation of murine DC in GM-CSF is a well-
established culture method (183). The results (Fig. 6C) demonstrated that rapamycin’s 
suppressive effect on DC maturation was IL-4 dependent as no significant inhibition of 
upregulation of MHC class II or costimulatory molecules was observed in the absence of the 
cytokine. Additionally, the T cell allostimulatory activity was unaffected (Fig. 6D). DC 
maturation was also not impaired when BMDC from IL-4R α-deficient animals were expanded 
with GM-CSF + IL-4 in the presence of rapamycin (Fig. 6E).  These data indicate that rapamycin 
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 inhibited IL-4 mediated DC maturation. Importantly, in all experiments, cells were gated on the 
DC-specific marker CD11c in order to analyze costimulatory molecule expression specifically 
on DC and to rule out confounding effects due to different total numbers of DC. 
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 Figure 6. The inhibitory effect of rapamycin on DC maturation is IL-4-dependent and 
mediated via FKBP-12 binding.  
BMDC were generated with GM-CSF ± IL-4 and analyzed on day 7. (A-B)  In the presence of 
IL-4, rapamycin (Rapa) inhibited cell surface expression of CD40, CD80, CD86 and MHC class 
II molecules and the allostimulatory activity of purified CD11c+ DC, whereas FK506 exhibited 
no effect. Competition for rapamycin’s intracellular receptor FKBP12 by a molar excess of 
FK506 (A; second column from right) antagonized the inhibitory effects of rapamycin on DC 
maturation. (C-E) In the absence of IL-4 (C-D), or in IL-4 receptor-α deficient mice (E), 
rapamycin exerted no inhibitory effect on DC surface expression of CD40, CD80, CD86, or 
MHC class II molecules, or T cell allostimulatory activity.  (A, C, E) Cells were gated on 
CD11c. The incidence of CD11c+ cells expressing the Ag of interest is indicated. Results show 
representative data from ten (A), three (B, E), five (C), and two (D) similar experiments. 
 
 
2.4.3. Rapamycin downregulates post-transcriptional expression of the functional IL-4 
receptor complex on DC 
To elucidate the underlying mechanism of IL-4 mediated DC maturation inhibition in the 
presence of rapamycin, we investigated expression of both chains of the functional IL-4 receptor 
(IL-4R) complex on purified DC at both the transcriptional and posttranscriptional levels by 
RNase protection assay and flow cytometry, respectively. The high-affinity functional IL-4R is a 
heterodimer composed of the IL-4R α chain (IL-4Rα; CD124) and the common cytokine 
receptor γ chain (CD132). The results revealed that while rapamycin suppressed cell surface 
expression of both CD124 and CD132 subunits, their mRNA expression was not altered (Fig. 7). 
These data suggest that rapamycin targets IL-4-mediated myeloid DC maturation via post-
transcriptional inhibition of both chains of the functional IL-4R complex and is in agreement 
with rapamycin’s potent inhibitory effects on protein translation (145, 190) .  
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Figure 7. Rapamycin suppresses DC high-affinity IL-4 receptor complex expression at the 
posttranscriptional level.  
BMDC were generated with GM-CSF + IL-4, purified by immunomagnetic-bead sorting and 
subjected to RNase protection assay or directly analyzed by flow cytometry. (A) Comparative 
RNase protection assay analysis indicates no effect of rapamycin (Rapa) on CD124 or CD132 
mRNA expression. L32 and GAPDH represent internal controls. (B,C) Downregulation of 
CD124 and CD132 cell surface expression by rapamycin. Cells were gated on CD11c. The 
incidence of CD11c+ cells expressing the Ag of interest is indicated. Results show representative 
data of three (A, B) and five (C) experiments.  
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 2.4.4. Rapamycin inhibits endocytosis by DC in an IL-4 independent manner 
After observing the inhibitory activity of rapamycin on DC maturation, we analyzed the Ag 
uptake ability of rapamycin-treated DC. As discussed in Section 1.1.1., DC maturation entails a 
sequence of events, including marked downregulation of Ag uptake (11). Immature DC, in turn, 
are known for their remarkable endocytotic capacity. Analysis of GM-CSF+IL-4 expanded, BM-
derived DC harvested at day 7 of culture revealed a reduced capacity of cells exposed to 
rapamycin to exhibit macropinocytosis of FITC-Albumin and mannose-receptor mediated 
endocytosis of FITC-Dextran. This was evident both with respect to the incidence (Fig. 8A, B) 
and the mean fluorescence intensity (MFI) of CD11c+ cells (Fig. 8D).  
Since previous experiments indicated that the inhibitory effect of rapamycin on DC 
maturation was IL-4 dependent (Section 2.4.2.), we expanded DC with GM-CSF only. 
Additionally, in order to determine more precisely the endocytotic activity of homogenous DC at 
the same stage of maturation, we specifically analyzed immature MHC IIlow DC. These 
experiments confirmed the inhibitory effects of rapamycin on DC endocytosis and indicated that 
they were not IL-4 related (Fig. 9A-C). Again, low concentrations of 1 ng/ml rapamycin (1.1 
nmol) were sufficient to significantly and markedly suppress endocytotic activity. Using 1 ng/ml 
rapamycin, the relative MFI of immature MHC class IIlo CD11c+ DC compared to controls was 
<42% and <32% with respect to FITC-Albumin and FITC-Dextran respectively (Fig. 9C).  
Given that the mean trough whole blood level of rapamycin in renal transplant patients is 17.3 
ng/ml (5 mg rapamycin/day) (186) and that the free plasma fraction is 8%, these concentrations 
are clinically relevant. When rapamycin was added at day 6 of culture, it still inhibited DC 
endocytosis, but the overall effect was weaker (relative MFI 69% and 53% for FITC-Albumin 
and FITC-Dextran respectively at 5 ng/ml rapamycin).  
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 2.4.5. Rapamycin’s inhibitory effects on DC maturation and endocytosis are not due to 
increased apoptosis 
Having established that rapamycin inhibited DC maturation and endocytosis, we analyzed 
whether these effects were due to increased apoptotic cell death. In contrast to a previous report 
regarding rapamycin-treated human monocyte- and CD34-derived DC (191), the incidence of 
apoptosis at day 7 of culture was consistently low (<10%), and was not affected significantly by 
rapamycin, even at a ‘supra’-pharmacological dose of 100 ng/ml, as determined independently 
by Annexin-V/7-AAD and TUNEL staining (Fig. 10A, B).  Similar results were obtained with 
GM-CSF+IL-4 expanded DC and at day 4 of culture (data not shown). 
To ascertain whether rapamycin increased the susceptibility of DC to apoptosis induction, 
we either stimulated DC propagated in GM-CSF+IL-4 with LPS only (in the absence of 
cytokines) or cultured DC with medium alone in the absence of any stimuli (LPS, cytokines), 
then analyzed apoptosis in CD11c+ DC, 24 and 72 hours later by Annexin-V/7-AAD staining. 
The results show that rapamycin inhibited DC death when cells were stimulated for an extended 
period with LPS only (Fig. 10C) but did not significantly affect DC death when cells were 
cultured for an extended period in the absence of LPS (Fig. 10D). Thus, it is unlikely that in 
these experiments rapamycin acts primarily on DC via apoptosis induction.  
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 2.4.6. Suppressive effects of rapamycin on DC maturation, endocytosis and apoptosis 
are antagonized by competition for FKBP12 binding 
To reveal whether the suppression of DC maturation and apoptosis were specific rapamycin 
related effects, we performed additional control experiments in the presence of a molar excess of 
the immunophilin ligand FK506. This structurally similar macrolide competes for rapamycin's 
intracellular receptor FKBP12 and thus prevents specific interaction of the rapamycin-FKBP12 
complex with mTOR and subsequent inhibition of TOR signaling (145). In fact, binding of 
rapamycin to FKBP12 and TOR inhibition can be antagonized in vitro by FK506 (192). Addition 
of a ≥ 10-fold molar excess of FK506 antagonized the inhibitory action of rapamycin on DC 
maturation (Fig. 6A), apoptosis (Fig. 10C) and endocytosis (Fig. 8A, B, D; 9A-C), indicating 
that these were related to FKBP12-mediated TOR inhibition. Although a near-complete 
antagonism could be achieved for most of rapamycin’s effects on DC, in some cases the 
antagonistic effect of FK506 was incomplete, especially with respect to mannose receptor-
mediated endocytosis. In this particular case, similar results were obtained over a wide range of 
drug concentrations (1-20 ng/ml rapamycin; 10-250 ng/ml FK506) and at different 
FK506/rapamycin ratios (10-55 molar). This suggested that other FKBP might also be involved 
in endocytosis inhibition. One candidate is FKBP25, that has >100 times greater binding affinity 
for rapamycin than FK506 (193). 
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 2.5. DISCUSSION 
Numerous studies have demonstrated rapamycin’s potent suppression of the effectors of immune 
responses, -T and B lymphocytes (145, 194), but its influence on DC, the most specialized 
inducers of immune responses, are not well understood. Here we provide comprehensive in vitro 
evidence that rapamycin potently targets functional DC activation. The principal findings of this 
study provide novel insight into the immunopharmacology of this agent and have implications 
with respect to the therapeutic application of rapamycin.  
First, rapamycin targets responsiveness to the key DC regulatory cytokine IL-4. This 
effect is associated with downregulation of the high-affinity IL-4R complex, which consists of 
the IL-4R α-chain and the common cytokine receptor γ-chain. The inhibitory effects on DC 
maturation are mediated through rapamycin’s intracellular receptor FKBP12. However, 
inhibition of IL-4-mediated DC activation is only one of several aspects by which rapamycin can 
interfere with DC function. Downregulation of the common cytokine receptor γ-chain, which is 
an indispensable component not only of the IL-4R, but also the functional IL-2R, IL-7R, IL-9R, 
IL-15R, and IL-21R complexes (195-198), may have important additional implications with 
respect to the immunosuppressive effects of rapamycin on DC and other cells. This finding 
matches with a recent series of reports regarding rapamycin’s inhibitory impact on various 
cytokine signaling pathways in DC.  Thus, rapamycin has recently been reported to inhibit GM-
CSF-induced human DC survival by disrupting this cytokine’s signaling pathways inside DC 
(199), whereas in murine DC, rapamycin suppresses autocrine IL-12 signaling through inhibition 
of Jak2/Stat4 pathway (200).   
Second, rapamycin inhibits DC endocytosis, providing evidence that it may interfere with 
immune responses at a very early stage. Strikingly, rapamycin disrupts the sequential pairing of 
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 DC Ag uptake and immaturity, thereby rendering them unable to both acquire and present Ag. 
This is in contrast to other anti-inflammatory drugs, like corticosteroids (201) or salicylates 
(141), that have recently been shown to suppress DC maturation and as a consequence, enhance 
their endocytotic activity. Our findings regarding inhibition of Ag-uptake were confirmed 
recently in rapamycin-treated human monocyte-derived DC (202). The precise mechanism(s) by 
which rapamycin inhibits DC endocytosis remains to be determined. In this context, it is 
important to note that the Rho GTPases CDC42 and Rac that interfere with the endocytotic 
activity of DC (203, 204) complex with and activate the p70 S6 kinase (205) that belongs to the 
central signaling pathway disrupted by rapamycin (145). In addition, rapamycin’s inhibition of 
TOR signaling downregulates protein translation and has been demonstrated to suppress actin 
synthesis (206).  These novel findings, coupled with parallel results in the human system, may 
provide further incentive for the use of rapamycin in clinical settings other than transplantation, 
e.g. in autoimmune disease.   
Third, rapamycin does not affect DC differentiation and viability in vitro. In contrast to a 
recent report indicating that rapamycin induced apoptosis specifically in DC in the human 
system (191), we found the frequency of apoptotic or dead cells to be consistently less than 10% 
in BM-derived, in vitro-generated, rapamycin-treated DC. Moreover, when DC were stimulated 
with LPS, rapamycin inhibited cell death in a dose-dependent, FKBP12-mediated manner. Thus, 
it is unlikely that rapamycin acts primarily on DC via apoptosis induction. It should be noted that 
there have been several reports that rapamycin can exert anti-apoptotic effects on different cell 
populations (207-210). It is of particular importance that comparatively large numbers 
(comparable to normal DC cultures) of rapamycin-treated, immature DC can be generated in 
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 vitro, since these cells could potentially provide a source as therapeutic vectors to be used in 
transplant tolerance induction regimens (see Chapter Four). 
In conclusion, we show in this chapter, for the first time, that rapamycin can enhance the 
tolerogenic potential of murine BMDC in vitro by interfering with their functional activation at 
different levels. These observations, while they need to be confirmed in vivo to further analyze 
the mechanistic actions of rapamycin as an immunosuppressant, provide insight into better and 
perhaps broader use of this agent in situations where immune dysregulation occurs.      
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 3. CHAPTER THREE4 
IMPACT OF RAPAMYCIN ON DC FOLLOWING IN VIVO ADMINISTRATION 
 
3.1. ABSTRACT 
Immunosuppressive agents are commonly and increasingly used in clinical medicine, not least 
because of the growing numbers of organ transplant recipients. Due to the complex nature of the 
immune system, studies that dissect the impact of immunosuppressants on each component of 
the system may potentially aid in better use of these agents. Here, building on our findings 
presented in Chapter Two, we have analyzed the influence of rapamycin on DC development and 
function in vivo. For these studies, normal or Flt3L-treated mice were injected with rapamycin 
(0.5 mg/kg/day) or the drug vehicle for 7-10 days. The data show that rapamycin significantly 
decreased (40-50% reduction; P<0.002) DC numbers in BM and spleen, both under steady-state 
conditions and Flt3L-mediated DC expansion. Freshly-isolated DC from rapamycin-treated mice 
were impaired in their ability to upregulate surface costimulatory molecules (CD80, CD86) and 
secrete TNF-α and IL-12p70. In vivo exposure to rapamycin also inhibited DC Ag uptake. 
Furthermore, T cells of mice that had been injected with freshly-isolated, purified DC from 
rapamycin-treated donors, showed significantly reduced proliferation, and IL-2 and IFNγ 
production upon restimulation with donor alloAgs.  
 
 
 
 
                                                 
4 Data presented in this chapter is excerpted from (178) and (179).  
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 3.2. INTRODUCTION  
Organ transplantation remains the only definitive treatment for various end-stage organ failures. 
Despite significant advances in this field, -especially in short-term graft outcomes-, long-term 
outcome continues to be limited due to several reasons. Transplant recipients almost invariably 
rely on life-long heavy immunosuppression and its devastating side effects. On the other side of 
the spectrum, lowering the level of immunosuppression almost always brings the risk of 
rejection. In addition, current immunosuppressive regimens have limited protective impact on 
generation of chronic rejection. In theory, it would be ideal to program the recipient’s immune 
system in advance to tolerate the new organ. Ag-specific tolerance can be achieved through 
several approaches in experimental animal models, however  this ‘holy grail’ of transplant 
immunology remains far from reach in clinical transplantation at the moment, except for a 
minority of cases -particularly liver recipients-, for reasons and mechanisms still to be 
determined. Unmistakably, any attempt to induce donor Ag-specific tolerance needs to be 
evaluated in animal models under cover of clinically available immunosuppression, as this would 
be the strict condition when these approaches are translated into clinical trials. It is therefore 
critical to determine the optimum conditions of immunosuppression, under which tolerance 
could be achieved. 
Current immunosuppressive regimens rely on inhibition of lymphocyte activation and 
proliferation, and not on DC:lymphocyte interaction where the crucial fate of the immune 
response appears to be determined. Since most of the mechanisms of tolerance induction require 
initial activation of lymphocytes, immunosuppressive drugs that disrupt pathways associated 
with T cell activation can interfere with the development of tolerance (175, 211-213). One 
exception is rapamycin, which allows AICD in alloreactive T cells, an effect that promotes 
tolerance induction (174, 175). This tolerance-sparing effect of rapamycin may partially be due 
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 to its impact on DC functions. In the previous chapter, we have shown, for the first time, that 
exposure to clinically relevant doses of rapamycin inhibits maturation and allostimulatory 
potential of BMDC. In this chapter, we investigated the impact of rapamycin on DC in vivo. Our 
aims were three-fold: 1) to test if the observed impact of rapamycin on DC in vitro can be 
translated in vivo; 2) to examine if in vivo administration of rapamycin has any effect on DC 
differentiation; and 3) to assess the immunomodulatory effect of i.v.-infused rapamycin-treated 
DC on alloimmune responses. The latter investigation bridges this chapter with the next, where 
rapamycin-treated DC will be used as therapeutic vectors for transplant tolerance induction.  
Our results show that in vivo administration of rapamycin interferes with DC antigen 
uptake, maturation, allostimulatory function and bioactive IL-12p70 production. Furthermore, 
these DC, when adoptively transferred, induce T cell hyporesponsiveness. We also show that 
rapamycin blocks the in vivo effects of Flt3L, a potent endogenous DC growth factor that also 
regulates the proliferation of hematopoeitic precursor/stem cells and monocytic precursors (214, 
215). These novel observations provide new insights into actions of rapamycin and have 
significant implications for the development of new therapeutic strategies in disease processes in 
which DC may play a crucial immunopathologic role.   
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 3.3. MATERIALS AND METHODS 
3.3.1. Animals 
Eight-to 12-week-old C57BL/10 (B10; H2Kb) and C3H/HeJ (C3H; H2Kk) mice were purchased 
from The Jackson Laboratory (Bar Harbor, ME) and maintained in the specific pathogen-free 
Central Animal Facility of the University of Pittsburgh Medical Center. 
 
3.3.2. In vivo DC expansion and rapamycin administration  
The in vivo effects of rapamycin were investigated in normal animals and in mice in which DC 
were expanded by administration of r human Flt3L (Chinese hamster ovary [CHO] cell-derived; 
10µg/day, intraperitoneally (i.p.); d1-10; Immunex, now Amgen, Seattle, WA). Rapamycin 
(Wyeth-Ayerst, Princeton, NJ) was dissolved in 51% PEG300, 5% polysorbate 80, 5% ethanol 
(vehicle, all reagents from Sigma). Mice were injected with rapamycin (0.5 mg/kg/d; i.p.) or 
vehicle for 7 or 10 days (d3-d10; d1-10). Due to the long elimination half-life, mice received a 
loading dose on day 1 (1.5 mg/kg), according to the recommendation of Mahalati and Kahan 
(216). 
 
3.3.3. DC isolation and purification  
Spleens were injected with 100 U/ml type IV collagenase (Sigma) in RPMI-1640, disrupted and 
chopped with fine scissors and the resulting cell suspension kept at 4°C. The remaining tissue 
fragments were digested in 400 U/ml collagenase/RPMI-1640 solution for 45 min at 37°C. 
Finally, the cells were pooled, passed through a strainer and washed in sterile, ice-cold, Ca2+-
free PBS. DC were further enriched by density gradient centrifugation using 16% w/v 
metrizamide (Sigma) in PBS at 1200 x g for 20 min at 4°C. BM cells were isolated from femurs 
and tibias and subjected to density gradient centrifugation. To obtain highly-purified DC 
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 populations for analysis of allostimulatory activity, cytokine production or their adoptive 
transfer, the cells were labeled with magnetic bead-conjugated anti-CD11c mAb (Miltenyi 
Biotec, Auburn, CA) followed by positive selection through paramagnetic columns (LS columns, 
Miltenyi Biotec) according to the manufacturer’s instructions. DC purity of 90-95% was 
consistently achieved.  
 
3.3.4. Phenotypic analysis of DC 
DC surface antigen expression was analyzed by flow cytometry as described in the previous 
chapter. FITC-, PE, CyChrome-conjugated or biotinylated mAbs used to detect expression of 
CD11c (HL3), CD40 (HM40-3), CD54 (ICAM-1; 3E2), CD80 (16-10A1), CD86 (GL1), IAb β 
chain (25-9-17), H2Kb (AF6-88.5), as well as isotype-matched control Igs and Streptavidin-
CyChrome, were purchased from BD PharMingen (San Diego, CA). Five × 105 cells were 
blocked with 10% v/v normal goat serum (10 min; 4 °C) then stained with mAb (30 min; 4 °C). 
Appropriate isotype-matched Igs were used as negative controls. The cells were analyzed using 
an EPICS Elite flow cytometer (Beckman Coulter, Hialeah, FL).   
 
3.3.5. Cytokine quantitation and allostimulatory activity  
IL-12p70 and TNF-α production were measured in 24h supernatants of LPS-stimulated (2 
µg/ml), immunomagnetic bead-purified DC (106/ml) using ELISA kits (Quantikine, BD 
PharMingen). LPS stimulation was performed in the presence of low dose GM-CSF (Schering-
Plough, Kenilworth, NJ; 50 U/ml RPMI-1640 culture medium) and graded concentrations (0-
1000 U/ml) of IL-4 (R&D Systems, Minneapolis, MN), where indicated. IL-2, IL-4, IL-10, and 
IFNγ were quantified in 72h supernatants of MLR cultures using reagents and procedures 
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 recommended by the manufacturer (BD PharMingen). Graded numbers of γ-irradiated (20 Gy), 
magnetic bead-sorted B10 DC were used as stimulators in 72h MLR with nylon-wool column 
purified allogeneic (C3H) splenic T cells as responders (2×105/ml) as described.  
 
3.3.6. Endocytosis  
Quantitative analysis of endocytosis was performed as described in Chapter Two. Five × 105 
cells were incubated with 500 µg/ml FITC-Albumin (Sigma) or 1 mg/ml FITC-Dextran (MW 
42,000, Sigma) at either 37 °C or 4 °C for 40 min. Endocytosis was stopped by two washes in 
ice-cold 0.1% sodium azide/1% FCS/PBS. Cells were stained for CD11c (HL3), and in some 
experiments, for MHC class II expression (IAb β-chain, 25-9-17) as described (mAbs from BD 
PharMingen).  
 
3.3.7. Statistical analyses  
Statistical analysis was performed using Student’s ‘t’ test or the Wilcoxon rank sum test. All 
tests were performed two-tailed; P<0.05 was considered significant.  
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 3.4. RESULTS 
3.4.1. Rapamycin suppresses DC generation in vivo  
To address its in vivo effects, we first analyzed the impact of rapamycin on DC generation in 
normal mice. Mice were injected with 0.5 mg/kg/day rapamycin for 10 days, then DC in spleen 
were purified and quantitated. Rapamycin administration significantly reduced (>50%) the 
number of DC in comparison to animals injected with the drug vehicle (Fig. 11A). To explore 
the effects of rapamycin on DC expansion in vivo under dynamic conditions, we expanded DC 
injecting the endogenous DC growth factor Flt3L for 10 days in combination with either 
rapamycin or vehicle. Using this model, we confirmed that rapamycin impaired DC expansion, 
as evidenced by 40-50% reduction in BM and spleen DC numbers (Fig. 11B, C). In Flt3L-treated 
animals, the inhibitory effect of rapamycin on cell expansion was apparent from the appearance 
and significant reduction in weights of the spleens (Fig. 11D, E). To ascertain whether this 
difference was due to an ongoing induction of DC death in response to rapamycin, we analyzed 
the incidence of cell death ex vivo. The rate of apoptosis in DC freshly-isolated from rapamycin-
treated animals was consistently low (≤ 8%, n=3/group), similar to data we obtained previously 
from in vitro BMDC cultures (Chapter Two). 
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 whereas the expression of MHC class II was unaffected (Fig. 12A, B). This pattern of reduced 
costimulatory molecule expression but unaffected MHC class II expression in response to LPS 
was detected reproducibly in spleen and BM DC (freshly-isolated) from both normal and Flt3L-
treated animals. To assess the in vivo effects of rapamycin on the capacity of DC to stimulate T 
cells on a per cell basis, animals were treated with 0.5 mg/kg/d rapamycin or vehicle (7-10 days) 
and DC purified by density gradient centrifugation and immunomagnetic-bead sorting to >90% 
purity, as determined by CD11c+ staining. DC generated in vivo in the presence of rapamycin 
were found to be less efficient stimulators of fully allogeneic naïve C3H T cells in 72h MLR 
(Fig. 12C). 
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 Figure 12. Effect of in vivo rapamycin administration on the surface phenotype and 
allostimulatory capacity of DC. 
Mice were injected with either rapamycin (Rapa) or the drug vehicle for 10 days (with or without 
Flt3L). Splenic DC were purified and stimulated ex vivo with LPS. The MFI (A) and relative 
MFI (B) of CD11c+ cells expressing the antigen of interest in comparison with cells from drug 
vehicle-treated control animals is indicated. (A) Typical data from one representative experiment 
on day 10 of treatment. (B) Each point represents a single experiment with 3-6 animals (with or 
without Flt3L per treatment group after in vivo administration of rapamycin. *P<0.01 vs. vehicle 
(Wilcoxon test). (C) Allostimulatory activity of freshly-isolated, immunogenic bead-purified 
B10 DC (H2Kb, IAb) from rapamycin- or drug vehicle-treated (10 days) animals. Mean 
proliferative activity of fully allogeneic C3H responder T cells (H2Kk, IAk) in 72h MLR (± SD) 
is shown.  *P<0.05 vs. control DC. 
 
 
 
3.4.3. In vivo administration of rapamycin inhibits DC endocytosis 
To investigate the in vivo relevance of DC endocytosis inhibition observed during our studies 
presented in Chapter Two, we analyzed endocytotic activity in splenic DC of animals that were 
injected with rapamycin (0.5 mg/kg/day, 10 days i.p.) or vehicle, and in which DC were 
expanded with Flt3 ligand as described earlier. After 10 days, the animals were killed and FITC-
Albumin and FITC-Dextran uptake by freshly-isolated splenic CD11c+ DC was analyzed. The 
phenotype of these DC was immature in both treatment groups. As shown in Fig. 13, CD11c+ 
DC of rapamycin-treated animals displayed a significantly reduced macropinocytotic activity, 
both with respect to the number of positive cells and the relative MFI (P=0.001 and P=0.002,  
respectively). Similar findings were obtained with respect to FITC-Dextran uptake (41.5% 
positive cells vs. 24.8% in rapamycin injected animals, P<0.05; relative MFI 74.7%, P<0.05).  
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 3.4.4. DC exposed to rapamycin in vivo induces allogeneic T cell hyporesponsiveness 
after adoptive transfer 
Next, we investigated the in vivo priming ability of DC isolated from rapamycin-injected animals 
by performing adoptive i.v. transfer of 5x105 purified DC into naïve, allogeneic C3H recipients 
(Fig. 14A). Control recipients were injected with DC purified from age- and sex-matched control 
mice that had been injected with drug vehicle. Two weeks later, the animals were killed, and 
recipient T cells were restimulated with donor splenocytes. T cells of mice that had been injected 
with DC purified from rapamycin-treated donors showed markedly reduced T cell proliferative 
responses compared to controls indicating that rapamycin impaired the in vivo priming efficacy 
of the DC (Fig. 14B, C), regardless to whether they are from normal or Flt3L-treated animals. 
We also examined the cytokine profile of challenged T cells primed by rapamycin-exposed DC. 
These T cells displayed significantly reduced IL-2 and IFNγ production (Fig. 15A, B), whereas 
IL-4 and IL-10 (Fig. 15C, D) secretion was not significantly affected in response to restimulation 
with donor alloAgs. 
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 3.4.5. In vivo administration of rapamycin promotes IL-4 hyporesponsiveness of DC and 
dramatically impairs TNF-α secretion 
Based on our in vitro finding indicating that rapamycin only affected IL-4-dependent DC 
maturation, we hypothesized that in vivo-generated DC might be hyporesponsive to IL-4. To 
address this question, we took account of the finding that IL-4 is a major inducer of bioactive IL-
12p70 production in DC.  Splenic DC harvested from animals injected with drug vehicle were 
then stimulated with increasing IL-4 concentrations in the presence of LPS, exhibited a striking 
increase in IL-12p70 production, in agreement with Hochrein et al. (217). By contrast, when DC 
from rapamycin-injected animals were stimulated in the same manner, IL-4-induced production 
of IL-12p70 was abrogated, in an IL-4 dependent manner (Fig. 16A, B). We then analyzed 
production of TNF-α, a second major pro-inflammatory cytokine induced in DC by LPS 
stimulation. In contrast to the IL-12p70 data, TNF-α production by purified DC was dramatically 
impaired at all IL-4 concentrations. This finding (Fig. 16C) suggested IL-4-independent 
suppression of TNF-α production by rapamycin. 
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 3.5. DISCUSSION 
Evidence accumulated in the past two decades has provided insight into how masterfully DC 
orchestrate the immune system, with their unique abilities to sense and react to various ‘danger’ 
signals. Albeit mostly beneficial -e.g. recognizing microorganisms-, this master role can, in some 
instances, lead also to immune dysregulation causing autoimmunity or transplant rejection. 
Therefore there is a clear need for identifying agents that can modulate DC functions in vivo. In 
this chapter, we have studied the impact of rapamycin on DC generation and functions in vivo. 
Our results show that in vivo administration of rapamycin inhibits upregulation of costimulatory 
molecule expression, as assessed by flow cytometry, and the in vivo priming capacity of DC in 
naïve, fully allogeneic recipients, as tested by adoptive transfer experiments. These findings were 
obtained in two different in vivo models, and suggest that rapamycin is effective at impairing DC 
activation. In addition, we found markedly reduced production of the pro-inflammatory cytokine 
IL-12p70 and TNF-α by DC isolated from animals injected with rapamycin. Our results also 
suggest that rapamycin can interfere with immune responses at a very early stage by inhibiting 
DC endocytosis, confirming the observations made in vitro. Thus, rapamycin targets a unique 
function of DC that influences the induction of immunity against microbial pathogens (e.g. 
Salmonella (218)) and allergens (219). This effect may also suppress indirect alloantigen 
processing following transplantation.  
Pharmacological suppression of DC proliferation and activation by rapamycin has 
important implications for impairment of immune responses at the level of the APC. These cells 
are of pivotal importance in pathological conditions where DC perpetuate chronic inflammatory 
immune responses, e.g. chronic graft vasculopathy (220), atherosclerosis (221) and autoimmune 
diseases (222). One disease that may be especially amenable to rapamycin’s inhibitory action on 
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 DC is SLE. Intriguingly, Blanco et al. demonstrated that serum from SLE patients contained 
elevated levels of IFN-α that induced normal monocytes to differentiate into DC (223). They 
were able to correlate disease activity with the capacity of patients’ serum to induce DC 
differentiation, and concluded that unabated induction of DC by IFN-α may drive the 
immunopathologic process in SLE (223). Farkas et al (224) reported that pDC, which represent 
the natural IFN-α producing cells, accumulate in cutaneous SLE lesions. In this context it is of 
interest that rapamycin has been reported to arrest pathophysiological changes in murine SLE 
(225, 226). Thus, based on the pathogenetic importance of altered DC function in SLE, results 
from animal models, and our present findings, we contend that rapamycin merits evaluation for 
the treatment of SLE.   
Interestingly, rapamycin inhibits not only the in vivo generation of DC under steady-state 
conditions in normal animals, but also Flt3L-induced in vivo expansion of DC. Through 
reduction of the total DC pool, this action compounds the inhibitory effect of rapamycin 
independent of its effect at the single cell level. As discussed in Chapter Two, we carefully tested 
the hypothesis that the observed effects might be related to apoptosis. Similar to results obtained 
in vitro, the frequency of apoptotic or dead cells was consistently < 10% in in vivo-generated DC 
obtained from animals injected with rapamycin. These findings indicate unexpectedly the 
potential of rapamycin for the treatment of hematological malignancies where increased Flt3 
signaling is involved in disease pathogenesis. Our data demonstrate that rapamycin effectively 
inhibits Flt3L-induced DC expansion in vivo, as well as accompanying splenomegaly. With 
respect to this finding, it is of interest that activating Flt3 mutations are present in >25% of 
patients with acute myelogenous leukemia and the most common form, internal tandem 
duplications, confers a poor prognosis (227-231). Therefore, in addition to the recently-published 
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 therapeutic effects of rapamycin on solid tumor progression and metastasis (232), this finding 
provides an incentive to examine the therapeutic effects of rapamycin in models of acute 
myelogenous leukemia.  
In summary, by using two different in vivo models, we have provided evidence that 
rapamycin potently targets functional DC activation and expansion in vivo, mirroring its effects 
in vitro. These findings provide new insight into the immunopharmacology of rapamycin, and 
also have significant implications for the development of new therapeutic strategies in disease 
processes in which DC may play a crucial role.  
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 4. CHAPTER FOUR5 
RAPAMYCIN-TREATED DC AS THERAPEUTIC VECTORS TO INDUCE 
TRANSPLANT TOLERANCE 
 
4.1. ABSTRACT 
Tolerogenic properties of DC, particularly those in the immature state, and their therapeutic 
potential are increasingly being recognized. Among several distinct approaches to generate 
stably immature DC, pharmacologic manipulation stands out as a promising and clinically 
applicable option. In the previous chapters we have demonstrated that rapamycin can inhibit DC 
maturation and their effector functions. Here, we examined the impact of rapamycin exposure on 
subsequent alloAg presentation by MDC via the indirect pathway. Rapamycin-treated, allogeneic 
donor cell lysate-pulsed host DC (Rapa-DC) were inferior stimulators of syngeneic T cells, 
compared to donor cell lysate-pulsed, otherwise untreated DC. Rapamycin exposure did not 
block alloAg uptake by DC in extended cultures nor impair their in vivo homing to splenic T cell 
areas after adoptive transfer.  T cells primed by rapamycin-treated, alloAg-pulsed DC showed 
decreased capacity to produce IL-2 and IFNγ, and were hyporesponsive to subsequent challenge 
via both the direct and indirect pathways, in an Ag-specific manner. When infused one week 
before transplantation, Rapa-DC significantly prolonged alloAg-specific heart graft survival. 
This effect was reversed by systemic IL-2 administration in the early post-operative period, but 
enhanced by either repeated infusion of the cells, or a short post-transplant course of FK506. 
These therapeutic effects, achieved by targeting both major pathways of allorecognition, provide 
the basis for a clinically-applicable strategy to suppress graft rejection. 
                                                 
5 Parts of the data presented in this chapter is excerpted from (233). 
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 4.2. INTRODUCTION 
As discussed elsewhere in this thesis, DC are BM-derived professional APC with the unique 
ability to both initiate and regulate immune responses (16, 80). The nature of the immune 
response elicited by DC depends on their state of maturation and functional differentiation, that 
is influenced by microenvironmental factors (microbial products, cytokines and cyclooxygenase 
metabolites) (181). In the immature state, DC are inherently tolerogenic (66) and can suppress T 
cell responses to self or foreign Ag (16).  By contrast, their maturation in response to 
inflammatory stimuli is associated with the acquisition of potent immunostimulatory function, 
linked to upregulated expression of cell surface MHC and costimulatory molecules. This 
dichotomous function of DC, combined with their remarkable plasticity, provides a basis for the 
design of DC-based therapeutic applications to either boost or regulate the immune reaction (23, 
137, 234). Owing mainly to the initial immunostimulatory role assigned DC, there has been 
considerable advance in the use of DC-based vaccines for cancer immunotherapy. Thus far, 
nearly 100 clinical trials using this approach proved the potential of DC-based, tailored cancer 
therapy, although optimization of this approach still remains to be achieved (234). In these 
studies, typically tumor Ag-pulsed, mature DC are used to induce Ag-specific antitumor T cell 
responses. 
By contrast, there has been little clinical testing of DC-based tolerogenic strategies. 
Immature DC can mature once administered in vivo, limiting their tolerogenic potential. It is 
conceivable that if immature, tolerogenic DC can be stabilized at that stage, then by mimicking 
cancer studies, Ags to which tolerance is desired can be derived through DC-based ‘negative 
vaccination’ strategies. We have shown in previous chapters that in vitro or in vivo exposure of 
DC to rapamycin inhibits their maturation, inflammatory cytokine (bioactive IL-12p70 and TNF-
α) secretion and T cell allostimulatory capacities. Thus, rapamycin appears to be a good 
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 candidate for pharmacological suppression of DC functions and the generation of DC with 
tolerogenic/immunoregulatory activity. Indeed, as demonstrated in Chapter Three, rapamycin-
treated DC induce T cell hyporesponsiveness to donor Ag following their injection into 
allogeneic recipients. 
In this chapter, we have further explored the immunoregulatory capacity of rapamycin-
treated DC in the context of alloimmune reactivity. More specifically, we have examined the 
function of rapamycin-treated DC in indirect alloAg presentation and their role in modulation of 
organ transplant rejection. Our results show that these cells can be loaded effectively with Ag 
derived from donor cell lysates to induce alloAg-specific T cell hyporesponsiveness in vivo. 
Furthermore, infusion of these rapamycin-treated, alloAg-pulsed DC (Rapa-DC) prior to 
transplantation prolongs fully MHC-mismatched heart allograft survival, in some cases 
indefinitely, in otherwise untreated mice. The regulatory effect of these DC is more marked in 
animals given a short, postoperative course of subtherapeutic FK506. These novel findings 
provide insight into clinically applicable strategies for immunomodulation using 
pharmacologically-modified DC of host origin for therapy of graft rejection, with implications 
for use of regulatory DC in other immune-mediated disorders.  
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 4.3. MATERIALS and METHODS 
4.3.1. Animals 
Eight- to 12-week-old C57BL/10 (B10; H2Kb), C3H/HeJ (C3H; H2Kk) and BALB/c (H2Kd) 
mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and maintained in the 
specific pathogen-free Central Animal Facility of the University of Pittsburgh Medical Center. 
Experiments were conducted under an institutional animal care and use committee-approved 
protocol and in accordance with National Institutes of Health-approved guidelines. 
 
4.3.2. Generation of BM-derived DC 
BMDC were propagated as described in Chapter Two. Briefly, BM cells were removed from 
femurs and tibias of C3H mice and depleted of erythrocytes by hypotonic lysis. Erythroid 
precursors, B lymphocytes and granulocytes were removed by complement depletion using a 
cocktail of mAbs (anti-TER-119 [TER-119], anti-B220 [RA3-6B2] and anti-Gr1 [RB6-8C5]; BD 
PharMingen, San Diego, CA) followed by incubation (45 min; 37°C) with low-toxicity rabbit 
complement (Cedarlane, Hornby, ON, Canada). The cells were cultured for 7 days in RPMI-1640 
with 10% v/v heat-inactivated FCS, L-glutamine, non-essential amino acids, sodium pyruvate, 
penicillin-streptomycin, HEPES, 2-mercaptoethanol (all from Life Technologies, Gaithersburg, 
MD), 1000 U/ml r murine GM-CSF (Schering-Plough, Kenilworth, NJ) and 1000 U/ml r murine 
IL-4 (R&D Systems, Minneapolis, MN). On day 2, 10 ng/ml rapamycin (Sigma, St Louis, MO) 
was added. Every 2 days, 75% of the culture supernatant was replaced with fresh cytokine-
containing medium (with or without rapamycin). On day 4, non-adherent cells were removed; on 
day 7, 50% or more of the non-adherent cells expressed CD11c.  
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 4.3.3. Phenotypic analysis of DC 
DC surface Ag expression was analyzed by flow cytometry on day 8 of BM culture, 24h after 
alloAg pulsing. Stimulation was performed with LPS (0.1 to 1 µg/ml, Escherichia coli serotype 
026:B6; Sigma) in the presence of low-dose GM-CSF (50 U/ml) in RPMI-1640 for 16h at 37°C. 
FITC-, PE- or CyChrome-conjugated, or biotinylated mAbs used to detect expression of CD11c 
(HL3), CD80 (16-10A1), CD86 (GL1), IAk α chain (11-5.2), H2Kb (AF6-88.5) as well as 
isotype-matched control Igs and streptavidin-CyChrome, were purchased from BD PharMingen, 
unless otherwise noted. Cells (5x105) were blocked with 10% v/v normal goat serum (Vector, 
Burlingame, CA) (10 min; 4°C) then stained with mAb (30 min; 4°C). Appropriate isotype-
matched IgGs were used as negative controls. The cells were analyzed using an EPICS Elite flow 
cytometer (Beckman Coulter, Hialeah, FL).  
 
4.3.4. Pulsing of DC and autologous MLR 
CD11c immunomagnetic bead (Miltenyi Biotec, Auburn, CA)—purified DC were incubated 
with allogeneic splenocyte lysates at a DC: splenocyte equivalent ratio of 1:10 for 24 h at 37°C. 
Normal B10 splenocyte lysates were obtained by three cycles of rapid freeze/thaw exposure in 
PBS. To disrupt DC:lysate clumps, the cells were washed extensively (3x, 700x g, 5 min) with 
PBS containing 5 mM ethylenediamine tetra-acetic acid (EDTA) following pulsing. Graded 
numbers of γ-irradiated (20 Gy) DC were then used as stimulators in 72 h MLRs with nylon-wool 
column-enriched syngeneic (C3H) splenic T cells as responders (2x105/ml) in 96-well, round-
bottom plates. For the final 18 h, individual wells were pulse-labeled with 1 µCi [3H] thymidine. 
The amount of radioisotope incorporated was determined using a β scintillation counter. 
Recombinant murine IL-2 (R&D Systems; 100 U/ml) was added at the beginning of cocultures, 
where indicated. Results are expressed as mean c.p.m. ± 1 SD of triplicates. 
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 4.3.5. Analysis of Ag uptake 
Uptake of cell lysates by C3H DC was analyzed by flow cytometry. Thus, B10 splenocytes 
(H2Kb+) were labeled with carboxyfluoroscein succinimidyl ester (CFSE) (Molecular Probes, 
Eugene, OR) according to the manufacturer’s protocol, prior to lysis. CFSE enters the cells 
freely and is cleaved by non specific esterases once inside. Cleaved CFSE binds to cellular 
proteins irreversibly for days to months. Following pulsing, the percentage of 
CD11c+CFSE+H2Kb- cells was quantified as Ag-loaded DC. 
 
4.3.6. Analysis of T cell apoptosis and intracellular cytokine expression 
T cells cocultured with DC at a 10:1 ratio were harvested on day 3 of MLR. Apoptosis was 
analyzed over time by staining externalized phosphatidylserine with FITC-annexin-V, in 
combination with the vital dye 7-amino-actinomycin D (7-AAD; BD PharMingen) according to 
the manufacturer's instructions. Cells were costained for CD3 (anti-CD3, 17A2; BD 
PharMingen) to allow specific analysis of DC by flow cytometry. For intracellular cytokine 
analysis, harvested T cells were restimulated with plate-bound anti-CD3 and soluble anti-CD28 
(37.51; BD PharMingen) in the presence of Brefeldin A (Sigma), -the latter to block cytokine 
secretion, for 5 h. After extracellular staining with fluorochrome-conjugated anti-CD3, CD4 or 
CD8 mAbs, cells were permeabilized with 1% saponin and stained for IL-2, IL-4, IL-5, IL-10 or 
IFNγ (BD PharMingen). Appropriate isotype-matched IgGs were used as negative controls. 
 
4.3.7. In vivo imaging of labeled DC and immunohistochemical staining of tissue sections 
DC were labeled green with PKH-67 (Sigma), according to the manufacturer’s protocol and 
infused i.v. (1.5x106 in 0.1 ml PBS) via the lateral tail vein. Spleen blocks were embedded in 
Tissue-Tek OCT (Miles Laboratories, Elkhart, IN), snap frozen in isopentane/liquid nitrogen, and 
stored at -80°C. Cryostat sections (8 µm) were fixed in 96% ethanol (10 min), blocked with 10% 
72 
 v/v normal goat serum, and incubated overnight (4°C) with biotinylated-anti-CD3 mAb. As a 
second step, slides were incubated with 1:3000 Cy3-streptavidin (Jackson Immunoresearch Lab, 
West Grove, PA), for 30 min at room temperature. Cell nuclei were stained with DAPI 
(4,6 diamidino-2-phenylindole; Molecular Probes, Eugene, OR). Slides were fixed in 2% 
paraformaldehyde, mounted in glycerol/PBS, and examined with a Zeiss Axiovert 
135 microscope equipped with appropriate filters and a cooled CCD camera (Photometrics 
CH250, Tucson, AZ). Signals from different fluorochromes were acquired independently, and 
montages edited using the Adobe Photoshop software program (Adobe Systems, Mountain View, 
CA). 
 
4.3.8. Vascularized heart transplantation 
Heterotopic (intra-abdominal) heart transplantation was performed from B10 to C3H mice, as 
described (46). Briefly, the heart was transplanted into the abdomen with end-to-side 
anastomosis of aorta to aorta, and pulmonary artery to vena cava, under methoxyflurane 
inhalation anesthesia (Medical Development, Springvale, Australia). Graft survival was assessed 
by daily transabdominal palpation. Rejection was defined as total cessation of cardiac contraction 
and was confirmed by histological examination. Animals received either no treatment or were 
injected i.v. with 1.5x106 immunobead-sorted alloAg-pulsed DC (day –7, or days –10, -3 and 0). 
A subtherapeutic dose of 1 mg/kg/day FK506 (Prograf® for i.v. use; Fujisawa Healthcare, 
Deerfield, IL) was administered i.m. for 10 consecutive days (days 0 to 9) in two groups.  For the 
IL-2 treatment protocol, recipient mice were treated with 60,000 U rhIL-2 (Proleukin®, Chiron 
Therapeutics, Emeryville, CA) i.p every 8 h for 3 days, starting 8 h posttransplant (235). Graft 
survival was assessed by daily transabdominal palpation. Rejection was defined by the complete 
cessation of cardiac contraction, and was confirmed histologically. 
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 4.3.9. Immunofluorescence staining of tissue sections  
Blocks from heart grafts were embedded in Tissue-Tek OCT (Miles Laboratories, Elkhart, IN), 
snap frozen in isopentane/liquid nitrogen, and stored at -80°C. Cryostat sections (8 µm) were 
fixed in 96% ethanol (10 min), blocked with 10% normal goat serum, and incubated overnight 
(4°C) with each of the following biotin-mAbs: anti-CD4, anti-CD8α, anti-Gr1 (all from BD 
PharMingen) or anti-F4/80 (Bachem). As a second step, slides were incubated with 1:3000 Cy3-
streptavidin (Jackson Immunoresearch Lab, West Grove, PA), for 30 min at room temperature. 
Cell nuclei were stained with DAPI (4,6 diamidino-2-phenylindole; Molecular Probes, Eugene, 
OR). Slides were fixed in 2% paraformaldehyde, mounted in glycerol/PBS, and examined with a 
Zeiss Axiovert 135 microscope equipped with appropriate filters and a cooled CCD camera 
(Photometrics CH250, Tucson, AZ). Signals from different fluorochromes were acquired 
independently, and montages edited using the Adobe Photoshop software program (Adobe 
Systems, Mountain View, CA). 
 
4.3.10. RNase protection assay  
The procedure was performed as described previously. Briefly, RNA was isolated from 5x106 
snap-frozen, magnetic-bead sorted DC using a total RNA Isolation Kit (BD PharMingen). RNase 
protection assay was performed using the RiboQuant Multi-Probe RPA System (BD 
PharMingen) with 32P-UTP-labeled antisense RNA probes specific for IL-2, IL-4, IL-10, IL-15, 
IFNγ and the housekeeping genes L32 and GAPDH according to the manufacturer’s instructions. 
Mouse RNA and RNA degradation controls were included. Yeast tRNA served as negative 
control. Quantification of bands was performed by densitometry (Personal densitometers 1; 
Molecular Dynamics, Sunnyvale, CA). The signals from specific mRNAs were normalized to 
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 signals from housekeeping genes (L32 and GADPH) run on each lane to adjust for loading 
differences. 
 
4.3.11. Statistical analyses 
Statistical analysis was performed using the two-tailed Student's ‘t’ and Mann-Whitney tests, and 
a P value of <0.05 was considered significant. Graft survival data were compared by Kaplan-
Meier analysis and the log-rank test. Results are expressed as means ± 1SD. 
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 4.4. RESULTS 
4.4.1. Rapamycin inhibits DC maturation and their subsequent capacity to stimulate T 
cells through the indirect pathway 
DC generated from C3H BM in the presence or absence of a clinically relevant concentration of 
rapamycin (10 ng/ml) were incubated overnight on day 7 with freeze-thaw lysates of B10 
splenocytes. Preliminary experiments revealed that a DC:splenocyte equivalent ratio of 1:10 was 
optimal for pulsing DC, and gave the most consistent results (data not shown). After pulsing, DC 
were analyzed for both spontaneous and LPS-induced maturation by flow cytometry. AlloAg-
pulsed, gated CD11c+ Rapa-DC showed decreased surface expression of CD80, CD86 and MHC 
class II (IAk) molecules compared with alloAg-pulsed untreated control DC (Fig. 1A). These DC 
were then washed extensively, purified by CD11c magnetic beading, and then used as 
stimulators of naïve C3H splenic T cells. Rapamycin-treated, alloAg-pulsed DC were poorer 
stimulators of T cells compared to alloAg-pulsed control DC (Fig.1B). Lysates alone did not 
exhibit a significant stimulatory capacity for allogeneic naïve T cells, demonstrating that the 
direct pathway, a possible contributing factor that may arise from contamination of lysates with 
intact splenocytes or membrane fragments, was not a significant contributor to the induction of T 
cell proliferative responses.  
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Figure 17. Inhibition of DC maturation and T cell allostimulatory function via the indirect 
pathway. 
(A) C3H BM-derived DC were generated as described in the ‘Materials and Methods’, in the 
presence or absence of 10 ng/ml rapamycin. Rapamycin inhibited cell surface expression of 
CD80, CD86 and MHC-II on gated CD11c+ cells on day 8, following alloAg pulsing. 
Upregulation of these molecules in response to LPS (1µg/ml) was also suppressed by exposure 
of DC to rapamycin. The mean fluorescence intensity of CD11c+ cells expressing the marker of 
interest is indicated. (B) B10 alloAg-pulsed, Rapa-DC were inferior stimulators of naïve 
syngeneic C3H T cells, compared to alloAg-pulsed control (Ctr) DC. The ratio of DC:T cells is 
indicated in parentheses. Data are representative of results obtained from three (A) and four (B) 
similar experiments. 
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4.4.2. Rapamycin treatment does not interfere with lysate uptake by DC 
To ensure that the suppressed T cell stimulatory activity observed was due to active regulation 
and not simply to decreased uptake of lysates by Rapa-DC, we pre-labeled B10 splenocytes with 
CFSE, a fluorescent reagent that binds stably to intracellular proteins, prior to cell lysis. Using 
the standard overnight pulsing protocol, we examined the uptake of lysates by CD11c+ cells 
using flow cytometry. To eliminate false-positive co-staining due to DC-lysate cell surface 
adherence, we used a fluorochrome-conjugated mAb against MHC class I expressed by the 
allogeneic lysates (H2Kb) and compared CD11c+CFSE+H2Kb- populations of control and Rapa-
DC (H2Kb is expressed by the B10-derived lysates, but is absent on the surface of C3H DC). As 
seen in Fig. 18, Rapamycin treatment did not significantly block lysate uptake by DC when the 
DC were incubated with allogeneic cell lysates for an extended time period.  
          
Figure 18.  Exposure to rapamycin does 
not block alloAg uptake by DC. 
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 4.4.3. Rapamycin treatment does not affect homing of DC to the spleen after their 
adoptive transfer, but confers capacity to suppress alloAg-specific responses 
Next, to explore their potential for delivery of tolerogenic signals in vivo, we examined the in 
vivo migratory capacity of Rapa-DC. Following i.v. infusion (1.5-2x106) into naïve C3H 
recipients, C3H Rapa-DC labeled (green) with the lipophilic marker PKH-67 localized to T cell 
areas in spleen (Fig. 19B) as efficiently as control DC (Fig. 19A), as our laboratory has shown 
previously for immature DC (236). To investigate the in vivo T cell priming ability of Rapa-DC, 
we isolated T cells from the spleens of recipient mice, 7 days after the adoptive transfer of these 
cells. The T cells were challenged ex vivo by either DC of B10 origin (Fig. 20A) or B10 lysate-
pulsed, C3H-derived DC (Fig. 20B). T cells that had been primed in vivo by alloAg-pulsed Rapa-
DC showed markedly decreased proliferative responses to secondary stimulation, via either the 
direct- or indirect pathways of allorecognition. This hyporesponsiveness was alloAg-specific, as 
T cells responded strongly to third party (BALB/c; H2Kd) DC (Fig. 20A). Addition of 100 U/ml 
of exogenous rIL-2 at the start of cultures abrogated this hyporesponsiveness and restored the T 
cell proliferative responses to levels similar to those of T cells primed by alloAg-pulsed, control 
DC.  
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Figure 20. AlloAg-pulsed, rapamycin-treated DC induce Ag-specific T cell 
hyporesponsiveness in vivo. 
AlloAg-pulsed (B10), immunobead-purified control (Ctr)- or Rapa-DC were adoptively 
transferred (i.v) to syngeneic C3H mice (1.5 x 106/animal). Seven days later, recipient animals 
were killed and splenic T cells challenged ex vivo with graded numbers of γ-irradiated allogeneic 
(B10) DC or third party (BALB/c) DC (A), or alloAg-pulsed syngeneic (C3H) DC (B). Mean 
proliferation of responder T cells in 72 hour MLRs is shown (± 1 SD). At the beginning of 
cocultures, 100 U/ml rmIL-2 was added to the groups indicated. T cells from non-immunized 
animals (naïve) were used as controls. Results are from a single experiment representative of 
four (each) experiments performed. 
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 4.4.4.  Rapamycin-treated, alloAgs-pulsed DC do not increase the incidence of T cell 
death but markedly inhibit T cell IL-2 and IFNγ production 
To investigate other possible mechanisms underlying the regulatory influence of Rapa-DC on 
alloreactive T cell responses, we tested their potential to promote T cell apoptosis in vitro. We 
harvested T cells from DC:T cell cultures on day 3 and assessed the percentage of early apoptotic 
(Annexin-V+/7-AAD-) and late apoptotic/necrotic (Annexin-V+/7-AAD+) T cells. As seen in Fig. 
21A, there was no difference in the incidence of T cell death between cultures in which control 
or rapamycin-treated, alloAg-pulsed DC were used as stimulators. We also performed 
intracellular cytokine staining of T cells from these MLR cultures. Whereas a significant 
proportion of T cells primed indirectly by alloAg-pulsed control DC expressed IL-2 and IFNγ, 
production of these cytokines was markedly reduced in T cells stimulated by alloAg-pulsed 
Rapa-DC (Fig. 21B, C). Expression of the Th2 signature cytokines IL-4, IL-5 and IL-10 was also 
decreased, but to a lesser extent, in these allostimulated T cells (Fig. 21D). 
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Figure 21. Rapa-DC suppress IL-2 and IFNγ production by T cells, without affecting the 
incidence of T cell death. 
Naïve T cells were cultured with alloAg-pulsed control (Ctr)- or Rapa-DC at 10:1 ratio for 3 
days. (A) Cells were then analyzed after staining of phosphatidylyserine externalization with 
FITC-annexin-V in combination with the vital dye 7-AAD. The incidence of CD3+ cells 
expressing the marker of interest is indicated. (B-D) T cells were also permeabilized and 
analyzed for intracellular cytokine production. T cells primed in vitro by alloAg-pulsed Rapa-DC 
produced lower amounts of IL-2 and IFNγ (B, C); nevertheless this was not selective for these 
Th1 cytokines as IL-4, IL-5 and IL-10 production (D) were also decreased compared to T cells 
primed with Ctr-DC. Numbers in upper right quadrants indicate percent positive CD3+ cells for 
the cytokines indicated. (C) Results of four different experiments are shown. Results are 
representative of three (A), four (B, C) and three (D) experiments. *P<0.05 vs. Ctr-DC (Mann-
Whitney test). 
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 4.4.5. A single infusion of alloAg-pulsed, rapamycin-treated DC prolongs alloAg-specific 
heart graft survival; multiple infusion leads to long-term survival 
Next, to explore the therapeutic potential of alloAg-pulsed, Rapa-DC in vivo, we employed a 
fully MHC-mismatched (B10 to C3H) heterotopic vascularized heart transplant model. In this 
model, B10 heart grafts are rejected by C3H recipients within 7-11 days (MST=9.1 days) without 
immunosuppressive treatment. Graft survival was improved minimally, although not 
significantly, when alloAg-pulsed, control syngeneic DC were infused i.v. on day –7 (Fig. 22). 
By contrast, a single infusion of donor alloAg-pulsed, rapamycin-treated DC prolonged graft 
survival significantly (MST=23.8 days; P<0.005). This effect was Ag-specific, as no graft 
prolongation was observed in the group that received Rapa-DC pulsed with third party (BALB/c) 
alloAg, and was reversed by systemic administration of 8-hourly rIL-2 for 3 days, commencing 
8h post transplant. In addition, the beneficial effect of donor alloAg-pulsed Rapa-DC was 
improved to a MST of 46.8 days (P=0.0005 vs. untreated; and P=0.0029 vs. Rapa-DC alone) by 
short-term administration of a subtherapeutic dose of FK506 (1 mg/kg/day, i.m., days 0-9), 
which alone did not prolong graft survival. Strikingly, repeated infusion of donor alloAg-pulsed 
Rapa-DC, but not Ctr-DC (x3; days -10, -3 and 0) led to indefinite graft survival (>100 days) in 
40% of otherwise unmodified graft recipients (Fig. 22).  
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igure 22. AlloAg-pulsed Rapa-DC prolong heart graft survival. 
lloAg-pulsed, control (Ctr)- or Rapa-DC of host origin were injected i.v. into syngeneic C3H 
ice, 7 days before the transplantation (day 0) of B10 heat grafts. FK506 (1 mg/kg/day) was 
dministered i.m. for 10 days (days 0-9) and IL-2 (60000 U/animal/8h) was administered i.p. for 
 days from the time of transplant, where indicated. Untreated, third party (BALB/c) lysate-
ulsed Rapa-DC-treated mice were used as control recipients. Alternatively, the alloAg-pulsed 
apa-DC or alloAg-pulsed Ctr-DC were infused i.v. x3 (days -10, -3 and 0) into otherwise 
nmodified graft recipients. Statistical differences are analyzed by the log-rank test. 
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 4.4.6. Analysis of mechanisms involved in prolonged graft survival in response to 
alloAg-pulsed Rapa-DC 
In order to elucidate the mechanisms underlying prolonged graft survival, we repeated transplant 
experiments. Recipient mice that were pre-infused once (on day -7) with alloAg-pulsed control- 
or rapamycin-treated DC, or those that were otherwise untreated, were killed on day 7, and grafts 
as well as spleens were harvested. Splenic T cells of Rapa-DC-treated recipients were 
hyporesponsive to challenge with donor alloAg (Fig. 23A), confirming that this effect observed 
previously in adoptive transfer experiments was contributing to graft prolongation. Graft 
histology of the same group revealed minimal tissue disruption (Fig. 23B), whereas grafts from 
the otherwise untreated controls were severely damaged, with heavy cellular infiltration. Further 
analysis of the grafts confirmed that on day 7, grafts were infiltrated by granulocytes, 
macrophages, CD4+ and CD8+ cells (Fig. 24). Strikingly, grafts taken from Rapa-DC-preteated 
recipients had markedly reduced levels of infiltration. Furthermore, the latter showed 
significantly reduced levels of IFNγ gene expression, compared to control grafts (Fig. 25 A, B). 
In all cases, pretreatment with alloAg-pulsed control DC appeared to have an 
immunomodulatory effect, albeit less than that of Rapa-DC, that can account for the insignificant 
prolongation of graft survival following their administration (MST of 10.4 days vs 9.1 days in 
the untreated group; Fig. 22).      
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Figure 24. Inflammatory cell infiltration into grafts on day 7 is reduced in Rapa-DC-
pretreated heart graft recipients. 
Immunofluorescence staining of heart grafts harvested from otherwise untreated (LH column) or 
control DC- (middle column) or Rapa-DC- (RH column) pretreated recipients. Decreased 
infiltration of GR1+ (red, top row), F4/80+ (red, second row), CD4+ (green, third row) and CD8+ 
(green, fourth row) cells into graft is evident following treatment with Rapa-DC. Results are 
representative of multiple sections at various levels from two animals in each group. 
 
88 
  
 
Figur
Seven
isolate
There
untrea
 
 
 
 
 
 
 AB
 
 
 
 
 
 
 
 
 
 
e 25. Intragraft IFNγ gene expression is decreased in Rapa-DC pretreated recipients. 
 days post transplant, recipients were killed and heart grafts harvested. Total RNA was 
d and analyzed for common inflammatory cytokine signals by RNase protection assay. 
 was a significant reduction in IFNγ gene expression in the Rapa-DC group vs. the 
ted group (*P<0.05, Student’s ‘t’ test). 
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 4.5. DISCUSSION 
DC, once known almost exclusively for their unrivalled capacity to stimulate immune responses, 
are now recognized increasingly for their roles in immune regulation and the 
induction/maintenance of tolerance (16, 23, 66). In the immature state, DC exhibit inherent 
tolerogenic properties, as they fail to provide adequate costimulation for T cell activation. They 
can increase pancreatic islet (45) and vascularized organ transplant survival (46, 48). DC can 
also delay the onset or regulate the severity of autoimmune diseases in animal models (91, 119, 
237, 238). In the transplantation setting, both donor and recipient DC contribute to immune 
responses that lead to allograft rejection (25, 26, 239-241). Direct alloAg presentation, mediated 
by donor APC, results in the activation of host T cells by allogeneic MHC and costimulatory 
molecules expressed on these donor APC. This in turn, leads to vigorous T cell proliferation and 
anti-graft effector immune responses. As donor DC undergo attrition, their role as presenters of 
alloAg subsides, and recipient DC, that can traffic to the graft, become the predominant APC 
(242). Emerging evidence suggests that, once recipient DC populate the graft, they convey and 
present alloAg indirectly to T cells, in much the same way as other Ags in the periphery are 
presented in the normal steady state (243).  
Reports of the induction by DC of peripheral tolerance to self or MHC class II Ags 
encountered in the absence of inflammatory stimuli (62, 98), coupled to evidence that direct 
alloAg presentation diminishes with time after transplantation, provide a strong impetus for 
targeting indirect allorecognition via DC-induced cross-tolerance. In healthy human volunteers, 
subcutaneous injection of Ag (influenza matrix peptide or keyhole limpet hemocyanin)-pulsed 
autologous, immature, monocyte-derived DC led to specific inhibition of Ag-specific effector T 
cell functions (73). Moreover, IL-10-treated human monocyte-derived DC induce T cell anergy 
via cross-presentation of phagocytosed necrotic fragments (118). Similarly, immature DC 
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 pretreated with N-acetyl-L-cysteine induce alloAg-specific T cell hyporesponsiveness after 
loading with apoptotic cells (244). Further, while mice infused i.v. with alloAg-pulsed peritoneal 
exudate cells (PEC) develop a delayed-type hypersensitivity (DTH) response similar to that of 
allograft recipients after challenge with the alloAg, i.v. infusion of PEC pulsed with alloAg in the 
presence of IL-10/transforming growth factor (TGF)-β results in an anti-inflammatory, “allograft 
acceptor-like” DTH (245). Herein we show for the first time, that DC exposed to rapamycin 
become resistant to maturation and induce Ag-specific T cell hyporesponsiveness via indirect Ag 
presentation. In this model, T cells cross-primed by alloAg-pulsed, Rapa-DC become 
hyporesponsive to subsequent challenge with the same Ag, not only through the indirect 
pathway, but also the direct pathway, providing evidence for regulation of both these major 
pathways of allorecognition by pharmacologically-modified DC.  
The Ag-specific T cell hyporesponsiveness induced by our approach appeared to be the 
result of Rapa-DC trafficking to secondary lymphoid tissue and active regulation of T cell 
function that was reversible by exogenous IL-2. Freshly-isolated immature DC differ from 
mature DC in that they cannot provide adequate costimulation (signal 2) and inflammatory 
cytokine (e.g. IL-12p70) support (signal 3) in conjunction with their ability to ligate TCR 
through Ag presentation (signal 1). Whereas stimulation of T cells by mature DC results in their 
activation, priming by immature DC causes T cell anergy (246). Different approaches to 
generation of either stably immature or “alternatively-activated” DC, such as those conditioned 
with IL-10 (247, 248), have been reported over the past few years. IL-10-conditioned DC (90) 
and Vitamin D3-treated DC (140) both induce allogeneic T cell anergy. Repetitive stimulation of 
human T cells by allogeneic immature DC generates anergic T cells with limited resistance to 
IL-2 stimulation (109). In a similar manner, rapamycin-treated DC become stably immature, and 
91 
 as demonstrated in previous chapters, lose their capacity to produce IL-12p70 and TNF-α upon 
LPS stimulation. Importantly, after exposure to rapamycin, DC retain their capacity to take up 
cell lysate Ag in extended overnight culture (16-24 h), in contrast to previous reports by us 
(Chapters Two and Three) and others (202) that concern inhibition of Ag uptake over much 
shorter periods (≤ 2h). Moreover, it should be noted that the overnight pulsing with cell lysates 
was performed in the absence of rapamycin. 
The T cell hyporesponsiveness induced by Rapa-DC was not the sole result of the cells’ 
inability to prime T cells effectively. It was rather due to immunomodulatory activity of these 
cells since T cells primed by Rapa-DC later responded strongly to 3rd party DC challenge, but 
responded to DC from the same donor comparatively poorly. These in vitro and ex vivo 
observations were confirmed by Ag-specific prolongation of organ graft survival following 
systemic infusion of alloAg-pulsed Rapa-DC. We also observed a striking inhibition of the two 
main mediators of the type 1 T cell response, i.e. IL-2 and IFNγ production by T cells stimulated 
with Rapa-DC. Although there was a clear balance shift in type 1 vs. type 2 T cell biosignatures 
in the MLR cultures, there was no increase per se in the expression of the latter (IL-4, IL-5 and 
IL-10). This universal T cell cytokine downregulation is likely a contributing mechanism to the 
effects of Rapa-DC in transplant models, as Th2 cells play a role in alloimmune responses (25) 
and can be sufficient for graft rejection (105, 106, 249). Furthermore, IL-4 is recognized for its 
stimulatory effect on IL-12p70 production by DC (217). Thus it is possible that by reducing IL-4 
production, activation of “bystander” APC in the recipient is also inhibited by Rapa-DC. In our 
studies, we were not able to demonstrate an increase in incidence or activity of T cells with 
previously defined Treg cell phenotype such as CD4+CD25+, in response to either in vitro or in 
vivo stimulation by Rapa-DC. It should be emphasized that the Treg cell analyses were done 7 
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 days after priming of T cells by Rapa-DC, and in light of current evidence showing requirement 
for repeated stimulation for generation of Treg cells, we cannot rule out their induction by Rapa-
DC as a possible mechanism in long-term graft survivors.    
Strategies to utilize DC for the induction of donor-specific tolerance and the prolongation 
of organ allograft survival have until now been concerned mainly with donor DC (46, 48, 87, 
250, 251), whereas studies exploiting recipient DC in therapeutic approaches to graft rejection 
have been limited. One exception is the use of DC-DC hybrids, that express MHC of both 
parental APC, to delay the onset of alloAg-specific graft-versus-host disease (GVHD) when 
engineered to overexpress CD95L (252). Recently, in a rat kidney transplant model, preoperative 
infusion of dexamethasone-treated immature F1 DC, followed by CTLA4Ig and a short 
postoperative course of calcineurin inhibition, was found to promote indefinite graft survival and 
immune regulation via the indirect pathway (253).  
It has also been shown that intrathymic or i.v. injection of recipient BM-derived or thymic DC, 
pulsed with immunodominant alloMHC-I-derived peptide, prior to transplantation, prolongs 
cardiac or pancreatic islet allograft survival in ALS-treated rats (50, 60, 61, 254). These latter 
effects have been attributed, in part, to the induction of central tolerance by the allopeptide-
pulsed DC, as they were abrogated when the recipient rats were thymectomized prior to cell 
infusion (51). Clinical application of this strategy, however, is limited by the necessity to identify 
unrelated donor MHC peptides. The advantage and comparative simplicity of the present model 
lies in the use of whole donor cell lysates, which constitute the complete library of donor alloAgs 
to be presented indirectly by Rapa-DC. This approach also permits Ag-specific 
immunomodulation, as opposed to alternative approaches that target recipient DC via 
pharmacologic treatment of the host, -a method shown to induce tolerogenic DC in graft 
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 recipients (255). The incomplete prolongation of graft survival we observed uniformly following 
a single infusion of the DC was presumably due to activation of T cells via the direct pathway, 
since once this early response was suppressed, albeit minimally, by a transient subtherapeutic 
dose of FK506 (which alone did not prolong allograft survival), rejection was more markedly 
and significantly delayed. Calcineurin inhibition might also work in other ways to augment the 
beneficial effect of pretreatment with alloAg-pulsed Rapa-DC, e.g. by inhibiting donor DC 
migration (256). Notably, we were able to enhance the tolerogenic potential of Rapa-DC by 
repeated infusion of the alloAg-pulsed cells, -40% of recipients in this protocol exhibited long-
term graft survival, confirming the hyporesponsiveness achieved to both direct and indirect 
challenge in vitro.     
In summary, rapamycin-treated, alloAg-pulsed host DC can induce Ag-specific T cell 
hyporesponsiveness in vivo and prolong the survival of MHC-mismatched vascularized heart 
allografts. This approach, that obviates systemic delivery of the DC-modifying pharmacologic 
agent, constitutes a clinically applicable, cell-based ‘negative vaccination’ strategy for 
suppression of allograft rejection. 
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 5. SUMMARY  
With the advancement in surgical techniques and modern pharmacological immunosuppression, 
human organ transplantation, -merely an experimental procedure 50 years ago, has become the 
therapy of choice for end-stage vital organ failure. This relatively novel ‘therapy’, however, is 
far from being the ideal ‘treatment’ for the majority of allogeneic organ graft recipients, as they 
rely on life-long immunosuppression and become chronically immunosuppressed. Thus, the next 
frontier in transplant immunology is to achieve therapeutic, drug-free, Ag-specific tolerance. 
Activation of T cell clones reactive to self Ags (or to ‘newly-self’ Ags in the case of 
transplantation) is believed to be the main mechanism underlying initiation of autoimmunity and 
transplant rejection. Although most known autoimmune diseases have a genetic component, due 
to involvement of complex environmental factors, it is hard to predict whether an individual will 
develop autoimmune reactivity before the disease is manifest. This, in turn, limits Ag-specific 
therapeutic approaches aimed at autoimmunity. By contrast, in transplantation, Ags to which the 
host will react can be predicted, even before they are introduced to the host’s immune system. 
Indeed in the U.S., live kidney donation (usually from a relative or spouse) exceeds cadaveric 
kidney donation. This ‘predictability’ in transplantation presents an advantage in this field for 
trials of tolerance induction. It is now well-documented that Ags, when introduced to the 
immune system under steady-state conditions, can lead to tolerance. Studies by others and us 
have consistently shown that immature DC can induce tolerance to Ags that they express in vivo. 
By virtue of their remarkable plasticity however, immature DC-based therapeutic tolerance 
approaches face the risk of instigating immunogenic responses should the DC ‘mature’ in vivo. 
In transplantation, for instance, both the inflammatory responses due to surgical trauma and 
ischemia-reperfusion injury can promote DC maturation and generation of subsequent 
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 alloimmune responses. It is therefore important to devise approaches to predictably prevent DC 
maturation in vivo. 
We have demonstrated herein that the commonly used immunosuppressant rapamycin 
inhibits spontaneous and TLR4-mediated maturation of MDC, without interfering with their 
ability to present Ag to T cells. Rapamycin-treated DC, either in vitro or in vivo, lose their 
capacity to produce inflammatory cytokines (IL-12p70 and TNF-α), and induce Ag-specific T 
cell anergy. This study, for the first time, demonstrates that stably-immature DC can be pulsed 
with complex antigenic mixtures (257), and used as therapeutic vectors to induce allograft 
tolerance. Under steady-state conditions before organ transplant, administration of rapamycin-
conditioned, donor Ag-loaded DC prolongs heart graft survival significantly. This effect is 
enhanced when the initial acute inflammation, presumably due to surgery, is controlled by a 
short, post-operative course of FK506, and abrogated by administration of exogenous IL-2.   
Rapamycin was found to inhibit DC maturation and inflammatory cytokine production in 
two different strains (B10 and C3H) and under two different experimental conditions (in vitro 
and in/ex vivo) in the mouse. DC pretreated with rapamycin remain immature after exposure to 
both LPS and allogeneic cell lysates. Rapamycin treatment also inhibits the DC response to IL-4 
(in vitro) and Flt3L (in vivo). In Chapter Two, we showed that the suppression of the IL-4-
mediated in vitro maturation of murine BMDC is due to downregulation of the IL-4R complex 
on these cells upon exposure to rapamycin. Due to the broad mechanism of action of rapamycin, 
however, it is likely that this effect is only partially responsible for the IL-4 hypo-
/unresponsiveness and intracellular IL-4 signaling pathways may also be affected. Indeed, 
rapamycin may be targeting a common signaling pathway for IL-4R and Flt3, hence blocking the 
DC differentiation and maturation associated with ligation of these receptors, as discussed in 
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 Chapters Two and Three. One possible common target is the JAK/Stat pathway that is active in 
signal transduction pathways of both receptors.  
We believe that data presented in this thesis provide a framework on which novel 
strategies to use tolerogenic DC as therapeutic vectors may be based. In the light of these 
findings in mice, we propose to use rapamycin-conditioned DC-based regimens to promote 
transplant tolerance in a clinically-relevant large animal model. Based on this work, and to 
achieve a reliable outcome, several important parameters still need to be evaluated. Although 
rapamycin-treated DC induce Ag-specific T cell hyporesponsiveness in vivo, suggesting they 
retain their immature phenotype after i.v. administration, we have not formally evaluated their 
response to maturation stimuli, other than those mentioned above. Therefore, it will be of interest 
to analyze the expression of TLR4 and other TLRs on the DC surface following their exposure to 
rapamycin, and their response to TLR ligands and CD40 agonism (CD40L). In order to achieve 
predictable, long-term graft survival, the dose, frequency and timing of rapamycin-conditioned 
DC administration will need to be optimized. Data presented in Chapter Three provide evidence 
for use of rapamycin in vivo to control activation of ‘intrinsic’ DC (of host and donor origin) 
post-transplant, that may synergize with the tolerogenic potential of pre-administered Rapa-DC. 
At present, the main predictable hurdle with translation of this approach to the clinic is the 
induction of apoptosis in human DC by rapamycin. Studies by two different groups (191, 202) 
have demonstrated that rapamycin, while not affecting differentiation of either monocyte-derived 
or CD34+ hematopoietic progenitor-derived human DC, reduces cell recovery up to 50%, under 
concentrations comparable to those used in this thesis (10 ng/ml). This difference could be 
attributed to the fundamental differences between mouse and human systems, and the distinct 
starting population in DC cultures. However, it should also be noted that timing and duration of 
97 
 rapamycin exposure are different in those and the current study, such that rapamycin is added at 
the beginning of human DC cultures, whereas we have opted to begin exposing murine cells to 
rapamycin on day 2.   
Studies presented in this thesis investigating mechanisms underlying prolonged graft 
survival will also need to be repeated in long-term graft (tolerant) survivors. As discussed in 
Chapters Two and Three, DC exposed to rapamycin either in vitro or in vivo have a potent, yet 
incomplete inhibitory impact on alloreactive T cell proliferation and inflammatory cytokine 
production. This is in parallel to the limited, albeit statistically significant reduction of intragraft 
IFNγ expression post-transplant, following a single injection of Rapa-DC. Since multiple pre-
transplant infusions of these cells lead to long-term graft survival in a fraction of the recipients -
in a strain combination where spontaneous graft acceptance never occurs-, it is reasonable to 
presume that mechanisms other than induction of T cell anergy by rapamycin-pretreated DC are 
in effect, e.g. generation/expansion of T cells with regulatory capacity. Pharmacologically-
modified (with dexamethasone) DC expressing both donor and host alloAgs (F1) have recently 
been shown to induce indefinite survival of rat renal allografts, through induction of indirect 
pathway Treg cells (253). It would be interesting, then, to look for Treg cells in bulk T cell 
populations stimulated repeatedly with Rapa-DC. Additionaly, Rapa-DC need to be investigated 
for their capacity to expand naturally occurring (e.g. CD4+CD25highFoxp3+) Treg cells.    
Although we have used exclusively donor alloAg to pulse DC in our work, other Ags can 
potentially be introduced to the immune system through ‘tolerogenic’ DC. Recent evidence has 
suggested that indirect pathway stimulation with autoAg in the context of transplantation may be 
an important mechanism leading to immune-mediated allograft injury. Development of 
autoimmunity to the autoAg cardiac myosin (CM) (in human cardiac transplant recipients) (258) 
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 and type V collagen (in human lung transplant recipients) (259) has been correlated with 
destructive immunity against the graft.  It has been suggested that these autoAgs, which are 
usually ‘hidden’ from immunologic surveillance, may be released during ischemia-reperfusion 
injury or during alloimmune-mediated injury to the graft.  CD4+ T cells reactive against CM 
have been isolated in a mouse model of heart transplantation (258).  Furthermore, anti-CM 
autoimmune responses appear to be associated with the development of chronic heart graft 
rejection. Given the potential pathologic implications of autoimmunity to CM in heart transplant 
recipients, the use of rapamycin-conditioned DC to tolerize recipients to CM may be 
advantageous.  
In addition to demonstrating its role in potentiating DC tolerogenicity, our findings also 
expand knowledge of rapamycin’s mechanism of action as an immunosuppressant. As outlined 
in Chapter One, rapamycin has been noted traditionally for inhibiting signaling pathways 
associated with activating/inflammatory cytokines in T cells. In light of our data, we hereby 
argue that rapamycin may also suppress production of these cytokines by T cells upon 
stimulation by rapamycin-pretreated DC. Since, in vivo, all immune cells are exposed to the 
agent, this effect is likely a component of overall immusuppression, demonstrating the 
importance of designing studies dissecting the impact of immunosuppressants on different cell 
types, rather than concentrating solely on effector T cell populations.  
In summary, the studies presented herein have provided insight into the fields of 
pharmacologic immunosuppression and DC manipulation. Our discovery that rapamycin 
enhances the tolerogenic potential of DC, and that these cells can be loaded with complex Ag 
mixtures to promote tolerance, will likely provide impetus to further investigate this and similar 
approaches to develop DC-based therapeutic vectors for the treatment of allograft rejection. 
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